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 A STUDY OF MICROBIOLOGICAL PROFILE IN OBSTRUCTIVE 
PULMONARY DISEASE IN A TERTIARY CARE HOSPITAL 
THANJAVUR. 
 
ABSTRACT 
 
 
BACKGROUND AND OBJECTIVES 
 
 COPD is a chronic slowly progressive disorder, characterized by airways 
obstruction emphysema, and chronic bronchitis,  often clinically grouped together and  
referred to as chronic obstructive pulmonary disease,  damages both the acinar level 
(emphysema) and bronchial level (bronchitis). Because of increase in smoking, 
environmental pollutants and other noxious exposures, the incidence of COPD has 
increased  leading to significant morbidity and mortality. Bacterial infections are the 
most commonobservable cause of acute exacerbation in COPD. Acute exacerbation is 
characterized by increase in cough, dyspnoea and sputum production. The aim of our 
study is to find out the prevalence of microbial pathogens in COPD patients, with 
special reference to antibiotic susceptibility and their resistance pattern from hospital 
data. 
 
SETTINGS AND DESIGN 
 
 It was a prospective study carried out at the Institute of Microbiology, 
Thanjavur Medical College in association with the Department of Thoracic Medicine 
at Thanjavur Medical College Hospital, Thanjavur from April 2016 to September 
2017. 
 
 
 
MATERIALS AND METHODS 
 
The study population consists of 100 patients admitted in Thoracic Medicine 
Unit presenting with signs and symptoms of COPD. All the respiratory samples were 
subjected to direct gram staining, culture, biochemical reaction and the isolates were 
identified according to standard techniques. Antibiotic sensitivity was done by Kirby-
Bauer method according to CLSI standard. 
 
RESULTS 
 
COPD was common in the age-group of 40-60. Tobacco smoking was strongly 
associated with the study group. Corpulmonale 46% was the most common 
complication. Positive bacteriological culture was obtained in 43% of cases. Mixed 
infection among COPD patients was found in 10% of culture positive cases. Sputum 
purulence was significantly correlated with  culture positivity.  
 
The commonest organism in the respiratory samples in COPD patients were 
gram negative bacteria 86% as compared to gram positive bacteria 14%. Among gram 
negative organisms Klebsiella pneumoniae 43% was the most commonly and 
significantly isolated organism followed by Pseudomonas aeruginosa. Prevalence of 
extended spectrum β lactmase       43%.Multi drug resistance in Pseudomonas 
aeruginosa  19%. Presence of  MRSA 50%. Among the fungal isolates were Candida 
albicans 41%, Aspergillus niger 23%, Aspergillus flavus 18% and Aspergillus 
fumigates 18%. Haemophilus influenza and Mycoplasma were not isolated. 
 
CONCLUSION 
 
 To conclude,gram negative bacteria were more frequently isolated in our 
patients. Early antimicrobial treatment depending on the antimicrobial sensitivity 
leads to reduction of increasing burden of antibiotic resistance. 
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INTRODUCTION 
 
 COPD is defined as a disease state characterized by airflow obstruction 
that is not fully reversible. It is usually progressive in nature associated with 
an abnormal inflammatory response of the lungs to chronic inhalational 
exposure from smokes, dusts and other air pollution. The physiological 
changes in the airways are due to loss of elasticity and recoil due to cigarette 
smoke.2-3 
 COPD is a leading cause of morbidity and mortality world-wide. The 
W. H. O. estimated that COPD is currently the sixth leading cause of death 
and disability world-wide. It is estimated that COPD will become the third 
leading cause of death world-wide by 2020 and fifth leading cause of 
disability4-5
. 
 Microbial infections in  respiratory tract  are most frequent than any 
other organ and account for the largest number of work-days lost in the 
general population; account for 20-40% of out –patient; and 12-35% of in-
patient attendance in a general hospital5-7, and COPD  is a leading cause of 
morbidity&mortality. 
 Microbial infections can result whenever the defence  mechanism of 
normal lungs are impaired. That is, alterations produced in the bronchial 
epithelium by the damaging action of smoking favour bacterial adhesion, and 
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colonization leads to chronic infections that contribute to progressive 
pulmonary damage (or) whenever the resistance of the host in general is 
lower, which includes chronic diseases, immunological deficiencies, treatment 
with immunosuppressive agents, leukopenia and usually virulent infection2.  
 The natural history of COPD is characterized by frequent exacerbations 
with an increase of cough, purulent sputum production and breathlessness. 
Majority of exacerbations are infectious in etiology. Childhood infections are 
probably a risk factor for the development of COPD. Chronic infections may 
lead to recurrent chronic inflammation for chronic bacterial colonization of the 
airways. It can potentially predispose to loss of lung function as well as 
increase the risk of exacerbation8,9. 
 Three classes of pathogens responsible for acute exacerbations of 
COPD by infecting lower respiratory tract are respiratory viruses, aerobic 
gram-positive and gram-negative bacteria and atypical bacteria4. 
 Patients with frequent exacerbations appear to lose lung function at an 
accelerated rate and exacerbations of COPD increase the rates of 
hospitalization and mortality and decrease the quality of life and increase 
economic burden8. 
 This condition is highly serious in our country. Air pollution and 
smoking are the highest risk factors in India which are the main causes of 
COPD that lead to increase in microbial infection12.  
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Empirical treatment was given for more than 80% of patients without 
proper investigation. So the effectiveness of treatment is decreased due to 
emerging new resistant strains leading to recurrent microbial infections4. 
 In our hospital we also noticed an increasing incidence of microbial 
infections in COPD patients. This led to conducting a prospective study in 
order to record clinical and microbiological observations and find out the 
bacterial and fungal etiology and anti-microbial sensitivity pattern of 
microbial infections in COPD patients so that anti-microbial treatment could 
be started early depending on the anti-microbial sensitivity results, that is 
important for better prognosis of disease and  improve the quality of  life of 
the patient.  
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AIMS AND OBJECTIVES 
 
1. To detect pathogenic organism, by microscopic examination of sputum 
samples. 
2. To isolate and identify aerobic bacteria and fungal agent causing microbial 
infections in COPD patients. 
3. To study the incidence of gram negative bacteria among the bacterial 
isolates 
4. To study the incidence of mycoplasma among the bacterial isolates 
5. To study the incidence of fungal agent causing COPD 
6. To determine antimicrobial susceptibility pattern of the various bacterial 
isolates in COPD patients. 
7. To determine the molecular characterization of the commonest isolated 
organism by polymerase chain reaction. 
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REVIEW  OF  LITERATURE 
 
 
 Pulmonary disease is the first clinical presentation and most frequent 
complication of COPD. And the most common manifestation of pulmonary 
disease is lower respiratory tract infection, particularly COPD  of bacterial 
etiology.  
 Incidence of  microbial infections are increased, whenever the defence 
mechanism of normal lung is impaired and with a degree of 
immunosuppression. 
 Smoking, ambient air-pollution and occupational exposure lead to 
increased risk of COPD. 
 
The lung defence mechanisms 
Can be interfered with many factors , such as the following:- 
1. Loss (or) suppression of cough reflex 
2. Injury to mucocilliary apparatus 
3. Interference with the phagocytic (or) bactericidal activity of alveolar 
macrophages 
4. Pulmonary congestion and edema 
5. Accumulation of secretion leading to bronchial obstruction.  
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EARLY HISTORICAL LANDMARKS OF COPD 
 The foundation of modern knowledge of the pathologic anatomy of 
pulmonary emphysema was laid by J. Gough in 195212 
 The appearance of enlarged respiratory air spaces on the surface of 
human lungs was first illustrated by Ruysch in 19615 
 In 1967, the Swiss physician Bonnet referred COPD as “Voluminous 
lung” and in 1769, the Italian anatomist Giovanni Morgagni reported lungs 
were “turgid” particularly from air3. 
 Followed by Mathew Baille in 1807 not only provided an earliest 
illustration and brief description of emphysema, but also pointed out its 
essentially destructive character. 
 In 1814, the British physician Charles Badham became the first to use 
the term bronchitis14 
 In 1821, Rine Laennac known as father of chest medicine had  
described the relationship between emphysema and chronic bronchitis13 
The spirometer which is key to the diagnosis and management of 
COPD was invented by John Hutchinson in 1846. 
In 1965 it was thought that Dr.William Brisco was the first person to 
use the term COPD. 
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HISTORICAL  BACKGROUND OF BACTERIAL INFECTIONS 
In 1885 the German – Austrian paediatrician Theodor Escherich 
discovered Escherichia coli 17 
 Klebsiella  pneumonia also called Friedlander’s bacillus was described 
in 1882 by a German microbiologist and pathologist Carl Friedlander. 
K.pneumoniae is best known as a pathogen of the human respiratory system20 
The genus is named by the German physician and bacteriologist Edwin 
Klebs. In 1882 Carle Gessard a chemist and bacteriologist from Paris, France 
discovered pseudomonas aeruginosa. 
 Sir Alexander Ogston, a British surgeon discovered  staphylococcus16 
 
MYCOPLASMA  PNEUMONIAE 
 Mycoplasma pneumoniae was first discovered by Pasteur, who called it 
a pleuropneumonia - like organism22 
 Later in 1898 Nocard and Roux isolated a micoplasma species in 
culture from bovine24. 
 Borrel in 1910 named these organisms as Asterococcus Mycoides21 
 Later in 1929 Nowak placed them under the term mycoplasma. It was 
first isolated in tissue culture from the sputum of a patient with primary 
atypical pneumonia by Eaton et al in 1944, and thereafter it became known as 
the Eaton agent25 
 In 1961 Marmionanf Goodbum postulated that the Eaton agent was a 
PPLO and not  a virus27 
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MYCOLOGY 
In 1839 Langenbeck identified an illness (typhoid fever) associated 
with the presence of a fungus23 
Berg in 1841 evidenced that  thrush is caused by a fungus23 
Audry in 1887 evidenced that the organism isolated from cases of 
thrush was a single kind of fungus, candida albicans, the form it takes 
depending on its growth medium. 
At the third international congress of microbiology in 1939,Martin 
adopted Christine Bearhout’s use of the genus Candida for nine species. 
Martin’s reclassification was done in 1940. 
Aspergillus was named by Pier Antonio Micheli, an Italian priest and 
biologist in172928 
In 1863, the species fumigatus was first described by a physician 
George W.Frensenius. 
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CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 The patient with diffuse pulmonary disease can be put in one of two 
categories2 
 Obstructive  Disease (airway disease) 
 Restrictive Disease 
 
Obstructive Disease –  
 Characterized by an increase in resistance to airflow, owing to partial or 
complete obstruction at any level from the trachea and large bronchi to 
terminal and respiratory bronchioles. 
 
Restrictive Disease – 
 Characterized by reduced expansion of lung parenchyma, with 
decreased total lung capacity. 
 
The major diffuse obstructive disorders are:- 
Emphysema, chronic bronchitis and asthma. 
 Expiratory airflow obstruction may result either from anatomic airway 
narrowing, classically observed in asthma or from less of elastic recoil 
of the lung, which characteristically occurs in emphysema. 
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DEFINITION 
 COPD  is defined as a disease state characterized by airflow obstruction 
due to chronic bronchitis or emphysema. The airflow obstruction which is 
generally progressive may be accompanied by airway reactivity and may be 
partially reversible2-3 
 Although asthma (reversible airway hyperactivity) is a distinct disorder, 
it may be a component of COPD in some patients.  
 COPD is associated with abnormal inflammatory response of the lungs 
to chronic inhalations exposure from smokes, dusts and other air pollutants. 
 
Chronic Bronchitis2 
 Is  defined as the presence of a chronic productive cough on most days 
for 3 months, in each of two consecutive years, in a patient, in whom other 
causes of chronic cough have been excluded. 
 
Emphysema –2 
 It is defined as abnormal, permanent enlargement of the distal airspaces 
distal to the terminal bronchioles  accompanied by destruction of their walls 
and without obvious fibrosis. 
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 Snider has popularized the use of a Venn Diagram that shows the 
relationships between chronic bronchitis, emphysema and asthma . 
 
 
RISK  FACTORS(8,12) 
1. Tobacco smoking – accounts for 80 – 90% of the risk of developing 
COPD 
2. Childhood lung infection – less than 14 years of age (bronchitis, 
pneumonia or whooping cough) 
3. Passive smoking – environmental tobacco smoking. 
4. Genetic consideration – Severe α1 Antitrypsin deficiency with a proven 
genetic risk factor for COPD. PiZ allele increase is the most common 
form of severe Alpha – AT deficiency  
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5.  Air pollution 
 - working in high foggy areas 
 - coal mining, steel mill 
 - industrial pollutions 
6. Indoor air pollution – rural indian women exposed to domestic    
         fuels using bio-massfuel 
7.Occupation – several occupational exposure including coal mining, gold 
mining and cotton textile dust have been suggested as risk factors for 
chronic air-flow obstruction. 
8. Men affected more than women (increased smoking in men) 
9. Increased age 
10. Low socio-economic status 
11. Chronic broncho-pulmonary infection – which causes airway damage 
and progressive airway obstruction 
12. Growth and nutrition – impaired growth in utero may be a risk factor for 
the development of chronic respiratory disease 
13. Atopy and airway hyperresponsiveness(AHR)_is associated with an 
asthmatic predisposition with associated allergic pneumonia in which 
AHR may be important in the pathogenesis of persistent airway 
obstruction.  
 
 
13 
 
CAUSES OF MICROBIAL INFECTIONS IN COPD 
a) INFECTIOUS AGENTS 
1) Respiratory viruses 
a) Rhino virus 
b) Corona  virus 
c) Influenza virus 
d) Para influenza virus 
e) Adeno virus and respiratory syncytial virus. 
2) Aerobic gram positive and gram negative bacteria 
3) Atypical bacteria 
 
b)  ENVIRONMENTAL FACTORS 
1. Includes change in temperature 
2. Humidity 
3. Air pollution 
4. Occupational exposure 
5. Smoke exposure 
6. Noxious gases and  
7. Chemical irritants 
c ) HOST FACTORS 
1. Patients with low socio economic status 
2. Nutritional and immune deficiencies 
3. Poor personal hygiene 
4. Lack of exercise and  
5. Life style modification 
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MICROBIAL ETIOLOGY OF COPD 
 
 
 
INFECTION COMMON LESS COMMON 
BACTERIA 
Streptococcus     pneumoniae 
Hemophilus influenzae 
Staphylococcus aureus 
Pseudomonas aeuroginosa 
Moraxella 
Legionella 
Nocardia 
 
MYCOPLASMA Mycoplasma pneumoniae 
Mycoplasma 
Pneumonia 
M.fermentants 
M. pirum 
M. penetrans 
M. genitallium 
 
FUNGI 
 
Pneumocystis carnii 
Histoplasma capsulatum 
Cryptococcus neoformans 
Aspergillus species 
 
 
Candida albicans 
Pencillium mareneffei 
Blastomyces 
dermatitidis 
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BACTERIAL INFECTIONS IN COPD 
 
  Bacteria has been isolated from the sputum in approximately 60% of 
exacerbations of COPD. The most common organisms isolated include H 
influenza ,Haemophilus  parainfluenzae, S.pneumoniae and M.catarrhalis 
 
  Most virulent organisms in the airways of severe chronic bronchitis 
patients with acute exacerbations include, staphylococcus aureus, 
pseudomonas species and members of  enterobactericiae family4 
 
 Atypical pathogens such as mycoplasma and Chlamydia species  seem to 
increase the risk of exacerbations   
 
  Last atypical organisms and viruses can cause  primary infections that 
can lead to severe airway inflammation enabling a secondary  increase in 
bacterial proliferation that can lead to  exacerbations 33 
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RESPONSIBLE  BACTERIA IN ACUTE   EXACERBATIONS OF 
CHORNIC    BRONCHITIS37 
 
a) COMMON BACTERIAL PATHOGENS (30 – 50%) 
 Hemophilus influenza 
 Hemophilus parainfluenza 
 Streptococcus  pneumoniae 
 Moraxella catarrhalis 
 
b)  LESS COMMON BACTERIAL PATHOGENS (10-15%) 
 Pseudomonas aeruginosa 
 Enterobactericiae other gram negative bacilli 
 Staph aureus and other gram positive cocci 
 
    C) ATYPICAL PATHOGENS (5-15%) 
 Chlamydia pneumoniae 
 Mycoplasma pneumoniae 
 
Among the gram negative bacilli  mucoid forming isolate klebsiella  is 
a predominant one and pseudomonas is also becoming dominant 
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INCIDENCE OF BACTERIAL INFECTIONS IN COPD 
Bacterium is a common cause of infection in COPD patients in a study 
by Timothy F murphy. Majority of them were gram negative organism. 65% 
showed positive culture for bacteria in  a study by Bari mar et al. 
 The organisms that commonly play pathogenic role in acute 
exacerbation of COPD are pseudomonas and klebsiella, Acinetobacter, 
Moraxella Catarrhalis and Enterobactericiae also contributed in exacerbation 
of COPD. 
 The prevalence  of  P.aeruginosa infection in AECOPD is estimated to 
the 4%. But increase to as much as in 13% patients, with advanced airway 
obstruction in a study by Lawra Martinez et al. 
 P.aeruginosa is isolated from sputum samples from 4-15%  adults with 
COPD.  
 
INCIDENCE OF MYCOPLASMA IN COPD 
 80% of the cases of acute exacerbations of Chronic Obstructive 
Pulmonary  Disease (AECOPD) have a infective etiology, atypical bacteria 
including mycoplasma pneumonia accounting for 5-10% of these61 
 There are two main subtypes of M.pnuemoniae frequently isolated from 
clinical specimens (su et al 1990) 
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 Atypical pathogens reference Laboratory Database attributes 12% range 
(11-15%) of global CAP incidence to M.pnueumoniae .(Arnold et al 2007) 
 Mycoplasma infection in India has been reported for 35% patients with 
community acquired pneumonia in both children as well as in adults48 
 
INCIDENCE OF FUNGAL INFECTIONS IN COPD 
 Fungal infections have emerged as a world–wide health care problem in 
recent years, owing to extensive use of broad-spectrum antibiotics, long term 
use of immunosuppressive agents,  increasing use of hyperalimentation and 
indwelling devices and the increasing population of terminally ill, debilitated 
and immunocompromised patients. 
 In recent years, Chronic Obstrutive Pulmonary Diseases (COPD) have 
been recognized as a risk factor for invasive aspergillosis which occur as a 
result of smoking tobacco or long term exposure to pollution caused by 
burning of wood and other biomass fuels49 
 Airway colonization by Aspergillus species is a common feature of 
Chronic pulmonary disease. 
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 Increased prevalence of Aspergillus species colonization was observed 
in COPD  patients,although other fungal infections such as colonization of 
Pnemocystis jiroveci are also possible. 
 C.albicans(60.5%) was the most frequently recoverd species by culture, 
followed by C.trophicalis(16%), C.krusei(15.5%) and C.globrata(8%). 
 1.63% of COPD patients had Aspergillus species in their lower 
respiratory  tract samples and 22.1% of these patients had probable IPA by 
Guiner et al. 
 The most common species of filamentous fungi was Aspergillus 
species. A.fumigatus(43.7%) A.flavus(31.2%), A.niger(6.2%) and, A.terreus 
(6.2%) 
 Huerta et al reported that the isolation rate of Aspergillus species from 
sputum species was 16.6%. In addition, Kurhade et al  and Shahid et al  
isolated Aspergillus species from sputum samples of 16.3% and 14.&% of the 
cases with chronic respiratory disease. 
Candida albicans was the most frequent isolate being recovered from 
42.9% of patients, followed by Aspergillus flavus(21.4%),Aspergillus 
fumigates (14%) and Aspergillus  niger (10.7%).60 
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MORTALITY AND MORBIDITY OF COPD 
 
 Nowadays, incidence of COPD has increased, so that in India, the 
occurrence of this disease has increased by 4.1% 
 It was found that COPD was the most common underlying disease 
(22%) in critically ill patients by Khasawnath et al. 
 Chronic Obstructive Pulmonary Disease is a major cause of mortality 
and morbidity across the globe. 
 According to World Health Organization estimates, 65 million people 
have moderate to severe COPD.  More than 3 million people died of COPD in 
2005 Corresponding to 5%  deaths globally. So it is estimated to be the third 
leading cause of death by 2030.62 
There are 30 million COPD patients in India.  
  India contributes a significant and growing percentage of COPD 
mortality estimated to be amongst the highest in the world i.e., more than 64.7 
estimated age  standardized death rate per 100,000 amongst both sexes62 
 The reported prevalence estimates have ranged from  2 - 22% in men 
and from 1.2  to  19% in women.63 
 The national burden was estimated to be 14.84 millon6 
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PATHOLOGY  (PATHOLOGICAL CHANGES IN COPD)1 
 
Cigarette smoke exposure may affect the large airways (2 mm 
diameter) and alveolar space changes in large airways cause cough and 
sputum, while changes in small airways and alveoli are responsible for 
physiological alterations.  
 
LARGE AIRWAY 
 Cigarette smoking often results in mucous gland enlargement and 
goblet cell hyperplasia 
 These changes are proportional to cough and mucus production that 
define chronic bronchitis  
 Goblet cells, not only increase in number but in extent throughout the 
bronchial tree 
 Patients may have smooth muscle hypertrophy and bronchial hyper 
reactivity leading  to airflow limitation 
 Neutrophil influx has been  associated with purulent sputum of upper 
respiratory tract infections that hamper patient with COPD 
 
SMALL AIRWAYS 
 The major site of increased resistance in most individuals with COPD 
is always 2 mm diameter. 
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 Characteristic cellular changes include goblet cell metaplasia and 
replacement of surface secreting clara cells ,  with mucus-secreting and 
infiltrating mononuclear inflammatory cells  
 Reduced surfactant may increase surface tension at the air- tissue 
interface, predisposing to airway narrowing ( or ) collapse  
 Loss of  bronchiolar attachments, as a result of extra cellular matrix 
destruction, may cause airway distortion and narrowing in COPD 
 
LUNG PARENCHYMA 
 Emphysema is characterized by destruction of gas-exchanging 
airspaces (or) the respiratory bronchioles, alveolar  ducts and alveoli. 
 These walls become perforated and latter obliterated with coalasence  
of small distant airspaces intora abnormal and much larger airspaces. 
 Emphysema is classified into distinct pathological types, the most 
important being centriacinar and pan acinar. 
 
(A) CENTRIACINAR EMPHYSEMA (CENTRI LOBULAR) 
Is more common than the panacinar type, constituting more than 95% 
cases.  This type most frequently associated with cigarette smoking  often in 
association with chronic bronchitis is characterized by enlarged  airspaces 
found in associated respiratory bronchioles (central (or) proximal part of the 
acini). 
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B. PANACINER EMPHYSEMA (PAN LOBULAR)  
In  this type, the acini are uniformly enlarged from the level of the 
respiratory bronchiole to the terminal blind alveoli .“ pan’’ refers to the entire 
acinus, tends to occur more commonly in the lower zones usually more severe 
at the bases. 
This type of emphysema is associated with ( α-AT) deficiency . 
 
 
PATHOGENESIS(1) 
 The Elastase-Anti elastase hypothesis–Elastin,  the principal component 
of elastic fibres, highly stable component of the extracellular matrix, that is 
critical to the integrity of both the small airways and the lung parenchyma. 
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 Patients with genetic deficiency in α AT, the inhibitor of the serine 
protease neutrophil elastase were at increased risk of emphysema. 
Inflammation and extracellular matrix proteolysis, upon exposure to 
oxidants from cigarette smoke, resulting in transcription of matrix 
metaloproteinase-9,  proinflammator cytokines,  interleukin-8 and tumour 
necrosis  factor α  leads to neutrophil recruitment Matrix metalloproteinases 
and serine proteinases most notably neutrophil elastase, work together by 
degrading the inhibitor of the other,  to lung destruction. 
 These three collagenases (MMP-1,MMP-8 and MMP-13) that initiate 
cleavage of interstitial collagens are also induced in both inflammatory cells 
and structural cells in COPD. 
 Ineffective repair of elastin and perhaps other extracellular matrix 
components result in airspace enlargement that defines pulmonary 
emphysema. 
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PATHOPHYSIOLOGY1 
 
 Persistent reduction in forced expiratory flow rates is the most typical 
finding in COPD. 
 Increase in the residual volume and the residual volume/total lung 
capacity ratio, non uniform distribution of ventilation and ventilation- 
perfusion mismatching also occur. 
Airflow obstruction 
 Patient with airflow obstruction, related to COPD have a chronically 
reduced ratio of FEV1/FVC. 
Hyperinflation 
 In COPD, there is often “air trapping”, increased residual volume and 
increased ratio of residual volume to total lung capacity and progressive 
hyperinflation. Hyperinflation helps to compensate for airflow obstruction. 
Gas exchange 
  Pulmonary hypertension cause corpulmonale and right ventricular 
failure due to COPD occurs, in those individuals who have marked decrease in 
FEV1 (<25% of predicted) together with chronic hypoxia (PaO2<55mmHg) 
 Non uniform ventilation and ventilation perfusion mismatching are 
characteristic of COPD-accounts for essentially all of the reduction in PaO2 
that occurs in COPD 
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MICROBIAL INFECTIONS IN COPD53 
 Potential pathways by which microbes could contribute to the course 
and pathogenesis of COPD identified. 
1. Childhood lower respiratory tract infection impair lung growth, and is 
reflected in smaller lung volumes in adulthood. 
2. Microbes cause a substantial proportion of acute exacerbations of chronic 
bronchitis which cause considerable morbidity and mortality. 
3. Chronic colonization of the lower respiratory tract by microbial 
pathogens, amplifies the chronic inflammatory response present in COPD 
and leads to progressive airway obstruction (vicious circle hypothesis) 
4. Microbial pathogens invade and persist in respiratory tissues, alter the host 
response to cigarette smoke (or) induce a chronic smoke imflammatory 
response and thus contribute to the pathogenesis of COPD. 
5. Microbial antigens in the lower airway induce hypersenstivity and 
enhances airway hyperreactivity and induce eosinophilic inflammation. 
 
FREQUENT EXACERBATIONS HAVE 
1. Impaired health status 
2. Reduced physical activity levels 
3. Increased lower airway bacterial colonization 
4. Accelerated lung function decline 
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STAGING OF COPD(3) 
 Depends on factors such as 
 Arterial blood gas levels 
 Time and distance walked 
 Sensation of dysponea and 
 Body mass index into the following 
 
a) ATS criteria 
 Stage 1 – FEV1   50 percent of predicted 
 Stage 2 -  FEV135 to 49 percent of predicted 
 Stage 3 -  FEV1<  35 percent of predicted 
 
b) ERS criteria  
 Mild – FEV1  70 percent  of predicted 
        Moderate - FEV1 50 to < 80 percent of predicted 
 Severe - FEV1 < 50 percent of predicted 
 
c)  GOLD criteria (See later for clinical severity) 
 Stage 1 FEV1  80 percent of predicted 
 Stage 2 FEV1   30 to < 80 percent of predicted 
 Stage 3 FEV1     < 30 percent of predicted 
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SPIROMETRIC  CLASSIFICATION  OF  CHRONIC OBSTRUCTIVE  
PULMONARY  DISEASE  
 
 
Stage I : mild     FEV1/FVC < 0.70 
      FEV1  80 percent  predicted 
Stage II : moderate    FEV1/FVC < 0.70 
      50% FEV1< 80% predicted 
Stage III : severe    FEV1/FVC < 0.70 
      30% FEV1< 50% predicted 
Stage IV : very severe    FEV1/FVC < 0.70 
      FEV1   predicted or FEV1 
      < 50% predicted plus chronic  
          respiratory failure. 
  
 Patients with stage 1 COPD usually do not have severe hypoxemia, and 
arterial blood gas analysis is not  required. For stage 2 and 3 arterial blood gas 
measurements should be done. 
 Most patients of COPD will be of stage 1 type. Patients of this stage 
with complaint of dyspnoee, should be investigated further. Stage 2 patients 
are only a minority. Stage 3 patients also include a minority of COPD cases 
and need specialized care. 
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RESPIRATORY FAILURE:  
 Arterial partial pressure of oxygen (Pa02) <  8.0 Pa (60mm Hg) with or 
without arterial partial pressure of CO2 (PaCO2) > 6.7 kPa (50 mm Hg) while 
breathing air at sea level. The characteristic symptoms of COPD are chronic 
and progressive dyspnoea, cough, and sputum production. Chronic cough and 
sputum may precede the development of airflow limitation by many years. 
This pattern offers a unique opportunity to identify smokers and others at risk 
for COPD, and to intervene when the disease is not yet a major health 
problem. Conversely, significant airflow limitation may develop without 
chronic cough and sputum production. 
 Stage I: Mild COPD: Characterized by mild airflow limitation 
(FEV1/FVC < 0.70, FEV1  80 predicted). Symptoms of chronic cough and 
sputum production may be present, but not always. At this stage, the 
individual is usually unaware that his or her lung function is abnormal. 
 Stage  II: Moderate COPD: Characterized by worsening airflow 
limitation (FEV1/FVC < 0.70, 50% FEV1< 80% predicted), with shortness 
of breath typically developing on exertion and cough and sputum production 
sometimes also present. This is the stage at which patients typically seek 
medical attention because of chronic respiratory symptoms or an exacerbation 
of their disease. 
 Stage III: Severe COPD: Characterized by further worsening of airflow 
(FEV1/FVC < 0.70,  30% FEV1<50% predicted) 
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CLINICAL PRESENTATION OF COPD PATIENTS 
SYPMTOMS 
1. Cough with expectoration 
2. Sputum is usually mucoid purulent (or) mucopurulent depending upon the 
superimposed infection. 
3. Increase in breathlessness 
4. Chest pain 
5. Fever 
6. Weight loss 
7. Increased fatigue 
 
PHYSICAL SIGNS 
1. Dyspnoea 
2. Tachypnoea 
3. Tacycardia 
4. Expiratory wheeze 
5. Fine inspiratory crepitation 
 
Signs of hyperinflation 
1. Barrel shaped chest with kyphosis 
2. Increase dantero posterior diameter and prominent sternal angle 
3. Flat diaphragm and reduced chest wall movement 
31 
 
 
In later stages 
1. Emaciation 
2. Cyanosis-visible in lips and nailbeds 
3. Reduced jugular venous pressure 
4. Polycythemia 
5. Edema 
 
COMPLICATIONS 
1. Pneumonia 
2. Corpulmonale 
3. Type1 respiratory failure 
4. Type2 respiratory failure 
5. Right ventricular failure 
6. Secondary polycythemia 
7. Cardiacfailiure 
8. Respiatory acidosis and coma 
9. Pneumothorax 
10. Sleep abnormalities 
11. High incidence of depression 
12. Comorbidities –coronary artery disease,deep venous thrombosis and 
pulmonary embolism 
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DIAGNOSIS OF COPD 
 Include history, physical findings and laboratory findings associated 
with microbiological investigations. 
Laboratory findings include: 
1. Haematological tests- 
o Hb estimation, 
o total leukocyte count, 
o differential count, 
o ESR, 
o blood glucose level,  
o blood urea , 
o Serum creatinine 
2. Pulmonary function tests 
3. Radiological studies 
4. Altered blood gas analysis 
5. Serology-typically performed by isoelecric focusing of serum,which 
reflects the genotype at the p1 locus for the common alleles 
6. PCR-molecular genotyping of DNA can be performed for the common 
PI alleles(M,S and Z) 
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MICROBIOLOGICAL INVESTIGATIONS 
 Are used to isolate and identify the organisms and to determine 
antimicrobial susceptibility pattern of the bacterial isolates. 
 Different types of samples are collected from lower respiratory tract to 
perform microbial investigations. 
 The most common samples are: 
 
A. NON INVASIVE 
1. Expectorated sputum 
 The most common sample and the least invasive, collected under direct 
supervision was sent to the laboratory for culture in lower respiratory tract 
infections 
 
2. Induced sputum 
 Induction of sputum was done using a nebulizer with 3% hypertonic 
saline for 15minutes and sputum was collected in sterile wide mouth 
containers. 
 
3. Gastric lavage 
 - in uncooperative patients 
 - in other disorders like neurological disorders and coma 
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B. MINIMALLY INVASIVE 
 Endotracheal aspirate 
C. INVASIVE 
1. Bronchial washings  
2. Bronchoalveolarlavage (direct aspiration of secretion, through a 
bronchoscope) 
3. Lung tissue 
 
1.MICROSCOPY 
 Direct microscopy examination 
 Helps in determining the quality of specimen and in predicting the 
likely pathogens by characteristic appearance 
2. STAINING METHODS 54,55,56 
 a. Gram stain 
 b. Acid fast stain 
3. ANTIGEN DETECITION 
For detection of atypical pathogens; 
a. DIF 
b. Capture ELISA 
a. Direct immunofluorescence test; 
 - detects the mycoplasma antigen directly in the clinical specimens. 
b.Capture ELISA Assay 
     - is available using monoclonal antibodies against P1adhesion  Antigen, 
35 
 
4. SEROLOGY 
For detection of atypical pathogens 
Specific antibody detection test 
1. Immunofluoresence assays 
2. Latex agglutination assays 
3. ELISA using protein P1 antigen 
Non specific antibody detection tests; 
1. Cold agglutination test : it uses human O blood  group RBC(I 
antigen) and test is carried out at 4°C 
5. POLYMERASE CHAIN REACTIONS  
 
a) Multiplex PCR 
b) Real time PCR 
 
PCR is an important technique , which gives confirmatory results and 
higher diagnostic yield along with conventional diagnostic methods.  
 
 
 
 
 
 
 
 
 
Identification of the Isolates 
Identification of the isolated strains was based on colony morphology, microscopic 
observation. The samples were sub cultured in LB broth and centrifuged to obtain cell pellet. 
To identify the isolated microorganism 16S rRNA gene was amplified with universal primers 
as a forward primer AGA GTT TGA TCC TGG CTC AG and as a reverse ACG GCT ACC 
TTG TTA CGA CTT. Sequencing analysis was carried out using AB Life sciences 3500 
genetic analyser.  The sequence data was further processed using online tool ncbi BLAST. 
https://www.ncbi.nlm.nih.gov/.   
 
Bacterial DNA after Amplification 
 
 
Sample 1: Klebsiella pneumoniae strain Amm2 16S ribosomal RNA gene, partial sequence 
accession no: KJ950284.1 
Sample 2: Escherichia coli strain ETEC 16S ribosomal RNA gene, partial sequence 
accession no: MF919609.1 
Sample 3: Staphylococcus aureus strain HZW450 chromosome, complete genome accession 
no: CP020741.1 
Sample 4: Pseudomonas aeruginosa strain ET05 16S ribosomal RNA gene, partial sequence 
accession no: MF398395.1 
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PCR  
 
The Polymerase Chain Reaction (PCR) is a powerful and sensitive technique for DNA 
amplification (1). Taq DNA Polymerase is an enzyme widely used in PCR (2). The following 
guidelines are provided to ensure successful PCR using NEB's Taq DNA Polymerase. These 
guidelines cover routine PCR. Amplification of templates with high GC content, high 
secondary structure, low template concentrations, or amplicons greater than 5 kb may require 
further optimization. 
Protocol 
Reaction setup:  
 
We recommend assembling all reaction components on ice and quickly transferring the 
reactions to a thermocycler preheated to the denaturation temperature (95°C).  
Component 25 μl reaction 50 μl reaction Final Concentration 
10X Standard Taq Reaction Buffer 2.5 μl 5 μl 1X 
10 mM dNTPs 0.5 µl 1 μl 200 µM 
10 µM Forward Primer 0.5 µl 1 μl 0.2 µM (0.05–1 µM) 
10 µM Reverse Primer 0.5 µl 1 μl 0.2 µM (0.05–1 µM) 
Template DNA variable variable <1,000 ng 
Taq DNA Polymerase 0.125 µl 0.25 µl 1.25 units/50 µl PCR 
Nuclease-free water to 25 µl to 50 µl   
Notes: Gently mix the reaction. Collect all liquid to the bottom of the tube by a quick spin if 
necessary. Overlay the sample with mineral oil if using a PCR machine without a heated lid. 
 
Transfer PCR tubes from ice to a PCR machine with the block preheated to 95°C and begin 
thermocycling.  
 
Thermocycling conditions for a routine PCR:  
 
STEP  TEMP TIME  
Initial Denaturation  95°C  30 seconds 
30 Cycles 95°C 
45-68°C 
68°C 
15-30 seconds 
15-60 seconds 
1 minute/kb 
Final Extension 68°C 5 minutes 
Hold 4-10°C   
 
General Guidelines:  
1. Template:  
 
Use of high quality, purified DNA templates greatly enhances the success of PCR. Recommended 
amounts of DNA template for a 50 μl reaction are as follows:  
DNA Amount 
genomic 1 ng–1 μg 
plasmid or viral 1 pg–1 ng 
2. Primers:  
 
Oligonucleotide primers are generally 20–40 nucleotides in length and ideally have a GC content 
of 40–60%. Computer programs such as Primer3 (http://frodo.wi.mit.edu/primer3) can be used to 
design or analyze primers. The final concentration of each primer in a reaction may be 0.05–1 μM, 
typically 0.1–0.5 μM. 
 
3. Mg++ and additives:  
 
Mg++ concentration of 1.5–2.0 mM is optimal for most PCR products generated with Taq DNA 
Polymerase. The final Mg++concentration in 1X Standard Taq Reaction Buffer is 1.5 mM. This 
supports satisfactory amplification of most amplicons. However, Mg++ can be further optimized in 
0.5 or 1.0 mM increments using MgCl2.  
 
Amplification of some difficult targets, like GC-rich sequences, may be improved with additives, 
such as DMSO (3) or formamide (4). 
 
4. Deoxynucleotides: 
 
The final concentration of dNTPs is typically 200 μM of each deoxynucleotide. 
 
5. Taq DNA Polymerase Concentration:  
 
We generally recommend using Taq DNA Polymerase at a concentration of 25 units/ml (1.25 
units/50 μl reaction). However, the optimal concentration of Taq DNA Polymerase may range 
from 5–50 units/ml (0.25–2.5 units/50 μl reaction) in specialized applications. 
 
6. Denaturation:  
 
An initial denaturation of 30 seconds at 95°C is sufficient for most amplicons from pure DNA 
templates. For difficult templates such as GC-rich sequences, a longer initial denaturation of 2–4 
minutes at 95°C is recommended prior to PCR cycling to fully denature the template. With colony 
PCR, an initial 5 minute denaturation at 95°C is recommended.  
 
During thermocycling a 15–30 second denaturation at 95°C is recommended. 
 
7. Annealing:  
 
The annealing step is typically 15–60 seconds. Annealing temperature is based on the Tm of the 
primer pair and is typically 45–68°C. Annealing temperatures can be optimized by doing a 
temperature gradient PCR starting 5°C below the calculated Tm.  The NEB Tm Calculator is 
recommended to calculate an appropriate annealing temperature. 
 
When primers with annealing temperatures above 65°C are used, a 2-step PCR protocol is 
possible (see #10).  
 
8. Extension:  
 
The recommended extension temperature is 68°C. Extension times are generally 1 minute per kb. 
A final extension of 5 minutes at 68°C is recommended. 
 
9. Cycle number:  
 
Generally, 25–35 cycles yields sufficient product. Up to 45 cycles may be required to detect low-
copy-number targets. 
 
10. 2-step PCR:  
 
When primers with annealing temperatures above 65°C are used, a 2-step thermocycling protocol 
is possible. 
 
Thermocycling conditions for a routine 2-step PCR:  
 
STEP TEMP TIME  
Initial Denaturation 95°C 30 seconds 
30 Cycles 95°C 
65-68°C 
15-30 seconds 
1 minute/kb 
Final Extension 65-68°C 5 minutes 
Hold 4-10°C    
11. PCR product:  
 
The PCR products generated using Taq DNA Polymerase contain dA overhangs at the 3´–end; 
therefore the PCR products can be ligated to dT/dU-overhang vectors. 
 
References: 
1. Saiki R.K. et al. (1985). Science. 230, 1350-1354. 
2. Powell, L.M. et al. (1987). Cell. 50, 831-840. 
3.  Sun, Y., Hegamyer, G. and Colburn, N. (1993). Biotechniques. 15, 372-374. 
4.  Sarkar, G., Kapelner, S. and Sommer, S.S. (1990). Nucleic Acids Res.. 18, 7465. 
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TREATMENT56 
 Important goals particularly against bacterial infections are 
1. Improve pulmonary function 
2. Relief of symptoms 
3. To reassess the cause of disease to reduce the risk of further 
exacerbation. 
 
Antibiotic treatment should always aim on 
Decreasing bacterial load, 
- To decrease airway inflammation 
- To decrease work of breathing and 
- To select appropriate antibiotic therapy 
is essential to control microbial infections. 
 
 Development of antimicrobial resistance is by far the most important 
one. New emerging strains develop resistance pattern to old classes of 
antibiotics-lead to determine sensitivity pattern. 
 
 The antibiotics should be chosen as per patients’ affordability, severity 
of exacerbation, bacterial spectrum and have the knowledge of local 
bacteriological profile. Among them, the prevalence of MRSA, ESBL, Amp C 
and MBL producers should be important. 
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 Multidrug resistant organisms are resistant to three (or) more group of 
antibiotics with different mechanisms of action. 
 Inadequate empiric therapy lead to emergence of multidrug bacteria 
(MDR).Although pseudomonas aeuroginosa and methicillin resistant 
staphylococcus aureus (MRSA) are the two common organisms, other MDR  
bacteria includes extended – spectrum beta lactamases (ESBL) containing 
gram negative bacilli—ESBL, AmpC, MBL and penicillin resistant 
streptococcus pneumonia.   
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1. BETA LACTAMASES IN GRAM NEGATIVE BACILLI:64 
a) EXTENDED SPECTRUM BETA LACTAMASES (ESBL) 
 ESBL’s are included in  Bush class A lactamases capable of 
hydrolyzing Pencillins, Oxyimnocephalosporins and Monobactams 
(Aztreonam) and inhibited by lactamase inhibitors (Clavulanic acid, 
Sulbactam, Tazobactam) but have no detectable activity against Cephamycins 
or Carbapenems (Imipenem, Meropenem) 
 Produced mainly by members of family enterobacteriaceae (Klebsiella 
and   E.coli, ) and some nonfermentors. 
 These  enzymes are carried on plasmid  and may spread rapidly from 
strain to strain, can be transferred between gram negative rods, even of other 
species. 
 Often mediate resistant to other antimicrobial agents, such as 
aminoglycosides, tetracycline and sulfonamides. 
 Recent surveys suggest that 50-70% 0f exacerbations are due to 
respiratory infections; 10% due to environmental pollution and upto30% are of 
unknown etiology. 
 Study for monitoring antimicrobial resistance program 2007 stated 
42.2% were ESBL positive. 
 Ecoli isolates were 42.2% positive and also 35.8% of  k.pneumonia 
isolates. 
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METHODS FOR DETECTION OF EXTENDED SPECTRUM  
BETALACTAMASES 
 
1. Screening methods: using cefotaxime / ceftriaxone cefpodoxime/ 
ceftazidime / cefepime 30microgram discs by disc diffusion method 
should be followed by confirmatory  methods. 
2. CLSI phenotypic confirmatory methods by both broth microdilution 
method and disc diffusion method. 
3. Double disc testing(DDT) 
4. ESBL E test. 
5. Automated methods.(MAST DISC TEST, Vitet card) 
6. Molecular detection methods. 
 
2.AmpC  BETA LACTAMASES65 
 Amp C  βlactamases are Bush class C  β lactamases (chromosomal or 
plasmid mediated) that degrades most cephalosporins and are resistant to   all 
beta lactamases (including Cephamycins) and are not blocked by beta 
lactamase inhibitor (Clavulanate, sulbactam or tazobactam) combinations 
except Carbapenems. 
 They can be differentiated from ESBL by their ability to hydrolyze 
cephamycins. 
 Multidrug resistant plasmid mediated Amp Cenzymes,seen in 
Klebsiella spp , E.coli , salmonella  and   p.mirabilis.65 
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 Studies from various parts of India have reported the prevalence  of Amp C 
in clinical isolates of enterobacteriace  as varying from  2.2% to 20.7% 65 
 
DIAGNOSTIC TESTS FOR AmpC DETECTION: 
1. Screening methods using cefoxitin disc by disc diffusion method,  
Organisms showing resistance to cefoxitin (zone size<18mm)should be 
considered as probable Amp C producer, and should be followed by 
confirmatory tests. 
2. Cefotetan DDT 
3. E test AmpC Strips contain cefatetan on one end and cefotetan-cloxacillin 
on the other end. 
4.  Molecular methods 
Multiplex PCR to detect plasmid mediated resistance using six primers 
(or) Amp C gene promoter sequencing to detect chromosomal promoter 
mutations. 
 
3. METALLO BETA LACTAMASES IN GRAM NEGATIVE BACILLI: 66 
 
 MBL are Bush class B β lactamases capable of hydrolyzing 
carbapenems by production of metallo beta lactamases. Carbapenem are the 
most potent agent for the treatment of multidrug resistant gram negative 
bacterial infections. 
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In recent years, there has been an increase in the prevalence of carbapenem 
resistance which is acquired metalo β lactamases(MBL) and found mainly in 
pseudomonas aeurginoa spp and Enterobactericaeae. Resistance to 
carbapenems may be due to impermeability through cell wall due to loss of 
omrDporin, up regulation of an active efflux system, carbapenems production, 
or production of MBLs.  
 The prevalence of imipenem resistance (carbapenems production) was 
observed in 40.3% isolates of acinetobacter spp and in 40-54 %  of 
pseudomonas 66 
 
DETECTION OF MBL 
1. Screening methods: using carbapenem disc (Doripenem, Ertapenem, 
Imipenem and meropenem),  followed by 
2. Confirmatory methods: Imipenem – EDTA DDT  
3. Modified Hodge test (MHT). 
4. MBL E test-imipenem on one end of the strip, imipenem+EDTA on the 
other end 
5. Molecular methods-PCR techniques using multiplex PCR detection for 
carbapenemes and sequencing of carbapenamase genes. 
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4. METHICILLIN  RESISTANT STAPHYLOCOCCUS AUREUS 
 MRSA is a major pathogen responsible for both hospital and 
community acquired infection. These are β lactamases, which are clinically 
resistant to all available β lactamases including penicillin, cephalosporins, β 
lactam/β lactamase inhibitor combinations, monobactam and carbapenems. 
The incidence of MRSA varies from 25% in western part of India to 50% in 
South India. Sangeetha et al 2010   
 β lactamases produced resistance by 
1. High level of β lactamases production 
2. Modification of normal penicillin biniding proteins (PBPs) and 
3. Presence of acquired penicillin binding protein (PBP2) 
  
 Resistant mechanisms in MRSA are by high level of β lactamase 
production (BORSA) or production of modified PBP2 (MOD-PBP) with 
decreased drug affinity  
 The vast majority of clinical strains that exhibit this type of resistance 
have acquired the mecA gene that encodes PBP2a which has decreased 
affinity for binding the compound. 
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DETECTION METHODS FOR MRSA 
1. Screening method-Routine disc diffusion procedure with cefoxitin disc 
(30µg)/oxacillin,followed by 
2.  Confirmatory method-broth microdilution screen usuing the CLSI 
breakpoint for S.aureus 
3.  E-test 
4.  Molecular detection of mecA gene using either a commercial latex 
agglutination test (or) 
Molecular detection methods detected PBP2. 
 Other PCR MRSA detection assays also used other staphylococcal gene 
markers –femA, femB, Sa442 and orfX. 
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MATERIALS AND METHODS 
 
 This prospective study was conducted at the Institute of Microbiology, 
Thanjavur Medical College in association with Thoracic Medicine 
Department. 
 
STUDY PERIOD 
 One year from April 2016 to September 2017 
 
STYDY POPULATION 
 The study population consisted of 100 patients, older than 18 years, 
admitted in Thoracic Medicine unit presenting with signs and symptoms of 
COPD.  
 
ETHICAL CLEARANCE 
 Institutional Ethical Committee approval was obtained, before the 
commencement of the study. From the study group, informed consent was 
obtained. By administrating structural questionnaire, the patients were 
interviewed. 
 
INCLUSION CRIETERIA 
 Patients with bronchial asthma, acute and chronic bronchitis and COPD 
were diagnosed by the clinician concerned depending upon the presence of 
two of the following symptoms. 
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 1. Increased sputum 
 2. Increased purulence or volume of expectoration 
 3. Increased severity of breathlessness 
 
EXCLUSION CRIETERIA 
 1. Outpatient status 
2. Evidence of bronchiectasis (or) pnemoniae, malignancy(or)severe 
immunosuppression and need for mechanical ventilation 
 3. Absence of an adequate sputum specimen(inappropriate sputum) 
 4. Treatment with any antibiotic within 24 hours before admission 
DATA COLLECTION 
 Complete data about the patient’s name ,age ,sex, hospital number, date 
of collection of  sputum, history of present illness and symptoms were 
collected from the patient. 
 Past H/O smoking , occupational history was also collected. 
 Any history of exposure to indoor air pollution was collected from the 
female patients. 
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SAMPLE COLLECTION, TRANSPORT AND PROCESSING 
 Patients were educated about the difference between sputum and oral 
secretion. Early morning samples were obtained from cases that were 
clinically diagnosed as COPD. Patients were instructed to collect coughed 
sputum into a sterile wide mouth container with a screw cap after rinsing the 
mouth twice with plain water. 
 Sample containers were labeled after the collection and were 
transported to the laboratory immediately and processed within 30 minutes of 
collection.  
 
SAMPLE COLLECTION 
 1. Expectorated sputum 
          2. Induced sputum (using a nebulizer with 3% hypertonic saline for 
15minutes) 
PROCESSING OF SPUTUM SAMPLES 
 Expectorated samples were used for isolation of bacterial and fungal 
pathogens. 
 
SAFETY PRECAUTIONS 
1. All sputum samples were potentially infectious and leak proof 
containers were used for collection and transportation of samples 
2. Biological Safety Cabinet level 111 was used for carrying out all 
procedures involving sputum and protective wears like mask, gloves etc. were 
used. 
47 
 
3. Disinfection of the sputum containers by treating with freshly 
prepared 1-2% sodium hypochlorite solution and autoclaving was following. 
The quality  of expectorated sputum was assessed by macroscopic 
examination and microscopic examination. 
Any sample that was thin, watery and with no purulent matter was 
considered unsuitable for further processing. 
 
A. DIRECT MICROSCOPY 
 All the respiratory samples i.e., sputum were subjected to the following 
microscopic examination. 
1. Direct gram stain 
 To detect the presence of bacterial cells, their gram reaction, 
morphology, arrangement and also to detect yeast cells. 
a.Direct Gram Smear:- 
The report had to  include the following information. 
 Whether many, moderate, few (or) scanty 
  Gram reaction of the bacteria, whether gram positive (or) gram 
negative 
 Morphology of the bacteria, whether cocci, Diplococci, streptococci, 
rods (or) coccobacilli. 
 Also whether the organisms are intracellular 
 Presence and number of pus cells. 
 Presence  of yeast cells and epithelial cells. 
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2. Acid fast stain 
 To detect the presence of mycobacterium tuberculosis bacilli in the 
sample. 
3. 10% Potassium hydroxide mount 
To detect the presence of fungal elements. 
 
B) HANGING DROP PREPARATION 
 Hanging drop preparation is one of the easiest methods to observe 
motility in a clinical microbiological laboratory. 
 Advantage of this method is that by this method, live bacteria can be 
observed. Examination of living organisms is useful to observe cell activities , 
viz., 
 Motility  
 Binary fission 
 Natural sizesand  shapes of the cells. 
 
Motility of Bactria  
        Can also be demonstrated by 
1. Craigie’s tube method 
2. Swarming  of the bacteria  on a non-inhibitory  medium (or) blood 
agar 
3. Dark ground microscopy 
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Procedure:- 
1. Take a clean grease free cavity slide. 
2. Take a clean cover slip; apply paraffin to the four corners of cover slip. 
3. Place a drop of broth culture on the cover slip, with the help  of 
inoculating loop. 
4. Place the cavity slide (cavity down) over the cover slip, so that the drop 
is placed in the center. 
5. Invert the slide and observe under microscope. 
6. First observe under low power (10X) 
Locate the edge of the drop, shift the focus to high power (40X) and 
observe. 
7.  Record the observation. 
 
 Sputum samples were mechanically homogenized with sterile glass 
beads using votex machine. All the sputum samples were prescreened with 
Gram stain, using Bartlett scoring system. Only those samples which met the 
acceptance criteria (a final score of > 0) were further processed for culture. 
Rest of the samples were discarded and repeat samples were obtainned in all 
possible cases. 
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BARTLETT SCORING SYSTEM ; BARTLETT’S GRADING SYSTEM 
FOR ASSESSING THE QUALITY OF SPUTUM SAMPLE: - 
 
No of Neutrophils per 10X low – power field:- 
                                   (Low – Power) 
                                         Grade 
< 10   0 
10 – 25 +1 
>25 +2 
Presence of mucus +1 
 
No of epithelial cells per 10 X low power field 
10 – 25 - 1 
> 25 - 2 
 
 A final score of 0 or less indicates lack of active inflammation (or) 
contamination with saliva. 
 
PREPARATON AND PROCEDURE FOR STAINING 
1. Gram’s stain procedure 
- Appropriate smear was made on a clean glass slide. The smear was 
fixed by passing the slide over flame 2-3times quickly. 
- The slide was covered with crystal violet solution and allowed it to 
act for 1 minute. Then  the slide was rinsed with water. 
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-  Holding the slide at an angle downwards pour on the Gram’s iodine 
solution on the slide for one minute. Then rinse the slide  with water. 
-  Pour a few drops of decolorizer to the smear (100% acetone) for 2to 3 
seconds. Rense the slide  immediately  with water. 
-  Apply the counterstain for 1 minute, rinse with water , blot dry and 
then examine the smear under oil immersion microscopy. 
 
2. Ziehl Neelson Staining Procedure; 
Preparation of smear 
- Select a new, unscratched slide and lablle with a laboratory serial number 
- Make a smear, from yellow purulent portion of the sputum. Spread a 
good smear  evenly, 2cmsx3cms in size and is neither too thin. The 
optimum thickness of the smear can be assessed by placing the smear on 
a printed matter, the print should be just readable  through the smear. 
- Let the smear air dry for 15-30 minutes. 
- Fix the smear by passing the slide over the flame 3-5 times ,for 3-4 
seconds each time. 
- Place the fixed slide, on the staining rack with the smeared slide facing 
upwards. 
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Staining; 
- Pour the smear  with strong carbol fuchsin for 5 minutes with 
intermittent heating by flaming the underneath of the slide until the 
fumes appear. 
- Allow the slide to cool for 5-7minutes. 
- Gently rinse the slide with water to remove the excess 
carbolfuchsin stain. 
- Decolourise the smear by adding 25% sulphuric acid for 3 minutes 
- Counterstain the slide by pouring 0.1% methylene blue solution for 
1 minute. 
- Gently rinse the slide with water and tip the slide to drain off the 
water 
- Place the slide in the slide tray and allow it to dry. 
- Then examine it under oil immersion objective. 
 
4. CULTURE: 
 The specimens were then plated into the following agar media. 
 Mac Conkey agar,5% Sheep bld agar, PPLO agar and Sabourauds 
dextrose agar. 
 All cultures were incubated at 37oc under aerobic condition and in a 
carbon dioxide enriched atmosphere. 
 Plates were evaluated for growth at 24 and 48 hours and discarded after 
5 days except for Sabouraud’s dextrose agar that was kept up to 4 weeks. 
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 MacConkey Agar   
1. Incubation  
Time – Upto 48 Hrs 
Temperature – 37oC 
Atmosphere – Ambient Air  
 2. Culture Reading – Daily  
 3. Pathogens That Grow – Enterobacteriaceae Non Fermenters   
 
 Blood Agar  
1. Incubation  
 Time – Upto 48 Hrs 
 Temperature – 37oC 
 Atmosphere – 5-10% Co2 
2. Culture Reading – Daily  
3. Pathogens That Grow – Streptococcus Species, Staph.Aureus, 
Moraxella Catarrhalis 
 
 Sabouraud Dextrose Agar  
1. Incubation 
 Time – Upto 4weeks  
 Temperature – 25oC and 370C 
 Atmosphere – Ambient Air 
2. Culture Reading – Daily  For 1 week, twice weekly for next 3weeks 
             3. Pathogens that grow – Fungi  
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 PPLO agar 
1. Incubation 
 Time – Upto 4weeks  
 Temperature – 25oC and 370C 
 Atmosphere – Ambient Air 
2.Culture Reading – 2-3 days interval for 1 week, and weekly twice for the 
next 3weeks 
3.Pathogens that Grow – Mycoplasma  
 
Report General Growth character as under:- 
( Depending on the medium used) 
>  General growth   >  colony characteristics   >  Surface characteristics  
> Margin / Edge of colonies > optical characters 
 
II. General growth 
On blood agar – presence or absence of haemolysis and swarming 
On Mac Conkey Agar – Presence or absence of lactose fermenting colonies  
Colony Characteristics : < Size and shape 
1. Size  
      -  the diameter in millimeters, after a specific duration of incubation. 
2. Shape : 
 - punctiform, Rocend / Circular, Elliptical, Irregular, Fusiform 
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III. Surface characteristics 
Of  colonies can be described as 
>smooth, > Contoured, >Radiate, > Concentric,  > wrinkled 
IV. Elevation Characteristics:- 
> Swarming,>Flat, > Raised, >Convex, >Pulvinte, >Umblicate,  
> Conical, >Umbonate 
V. Margins / edges of colonies:- 
 Entire, Undulate, Lobate, Lacerate, Fimbriate, Cilate. 
 
VI. Optical characters 
1. Pigment Production  ( Describe) 
 Colour of the pigment 
 Whether pigment restricted to the colonies ( insoluble pigment) 
 Whether pigment is dispersed in the medium surrounding colonies 
(soluble pigment) 
2. Opacity  
 Transparent, Opalcent, Opaque, Dull / Matt, Glistening / Fluorescent 
/ Mucoid 
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INTERPRETATION OF BACTERIAL CULTURES 
 
 The isolated colonies were identified by means of Garam’s stain 
motility, catalase, oxidase test and coagulase test and by various biochemical 
reactions like Indole test, Metyhl red test, Voges Proskauertest Citrate 
utilization test Ureasetest Triple Sugar iron agar, Hugh Leifson’s Oxidation 
fermentation test were performed .Sugar fermentation tests with sugars viz 
Glucose, Lactose, Sucrose, Maltose, Manose. Xylose, Arabinose and Dulcitol 
etc were done to identify the isolate according to Standard laboratory 
procedures. 
 
IDENTIFICATION OF MYCOPLASMAS:- 
 
1. DIENE’S STAIN PROCEDURE FOR 
 
Mycoplasma colonies are easily identified by observing typical 
colonies. On agar medium visualization of colony morphology is facilitated  
by application of Diene’s stain directly to the agar foreface. 
 
Diene’s stain: - 
 Is a non specific stain, that imparts a contrasting appearance of 
mycoplasma colonies. on agar, allowing easier visualization of colony 
morphology and characteristics. 
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Reagent: -   Diene’s Stain: - 
 Methylene Blue 2.5gms 
 Azure   blue     1.2 gms   
 Maltose     10.0gms 
 Na2 Co3        0.25 gm 
Distilled water 100.0 ml  
Procedure :- 
1. Flood an agar plate containing mycoplasma growth with 1 ml of Diene’s 
stain working solution. 
2. Immediately rinse the agar surface with distilled water to remove the stain. 
3. Decolorize the medium by adding 1 ml of 95% ethanol. Leave in contact 
with the agar for1 minute, then remove. Repeat the wash step a second 
time. 
4. Rinse  with distilled water and allow it to dry. 
5. Observe the colonies under the low power of a microscope 
 
2. RESULTS:- 
INTERPRETATION 
Mycoplasmas with the “Fried – egg” colony morphology will stain with 
a dark blue centre and light centre periphery and will appear highly granular. 
The agar background will be clear (or) slightly violet. 
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Mycoplasmas other then M pneumoniae will remain stained. 
M pneumoniae reduces the methylene blue after a time and will become 
colorless 
 
II. HEMADSORPTION TEST: 
 Among the respiratory Mycoplama , M pneumoniae is the only species, 
that will specifically absorb red blood cells. 
This property, therefore, provides a method for the presumptive 
identification of M pneumonia.  
When colony growth is noted on mycoplasma isolation media 
inoculated with respiratory tract specimens, a suspension of guinea pig 
erythrocytes is placed on the agar surface for a given time  thenwashed offM 
pneumoniae colonies will adsorb some of the red cells to the colony surface. 
 
 
Reagents:- 
1. Mycoplasma glucose agar with suspicious coloumn present. 
2. Washing guinea pig erythrocytes (0.2 – 0.4%) suspended in 
mycoplasma broth medium 
 
III. Procedure:- 
1. Flood the surface of agar with 2 ml of red cell suspension. 
2. Incubate the plate at 350Cfor 30 minutes and rotate the plate 
occasionally to prevent the red cells from setting out. 
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3. Wash the surface of the plate three time with 3 ml of Mycoplasma 
broth by gently rotating the plate. Remove wash fluid by aspiration 
with a pipette. 
4. Examine the colonies at 50 to 100 X magnifications under a 
dissecting microscope. 
 
Positive test :- colonies with red cells adsorbed onto the surface – M. pneumonia 
 
Negative test : - colonies with no red cells adsorbed – Mycoplasma species, 
not M. pneumonia. 
 
III. GLUCOSE FERMENTATION 
      Sterile PPLO broth with 0-5% glucose with PH – 7.8 prepared as 
described  above and about 2 ml of medium was dispensed in 13X 100 mm 
sterile screw capped tubes   0.2 ml of positive broth culture was inoculated and 
incubated aerobically at 37o C  for 10 days. Fermentation status was checked 
daily. A change in color from purple to yellow was noticed   
 
IV. ARGININE HYDROLYSIS 
Sterile screw capped tubes containing 2 ml of Arginine broth with 0.25% 
arginine at PH 7.0 was inaculated with 0.25 ml of broth culture of the isolates 
and inculcated aerobically at 37oC for 10 days. 
The result of hydrolysis was checked daily by observing a color change 
from purple to red. 
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V. UREA HYDROLYSIS:- 
        Ten percent of urea  was incorporated into PPLO broth media at a final 
Concentration of 1 % in the media and PH of the medium was adjusted to 6.5 
Screw capped tubes with sterile medium were inoculated 0.25ml of broth 
culture of the isolate and incubated aerobically at 35oC for 10 days. 
Urea breakdown was checked based on observing colour change from 
purple to red.  
 
VI. SEROLOGICAL TESTS:- 
      About 2 ml of blood was centrifuged and serum was separated and 
commercially available mycoplasma pneumoniae  IgM TMB ELISA (Bio Rad 
Laboratories) was done according to manufacturer’s instructions applied in the 
kit. 
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IDENTIFICATION OF FUNGUS 
9. Potassium Hydroxide Wet Mount Preparation 
Procedure: - 
1. Emulsify the specimen in a drop of 10 % KOH on a microscope 
slide with the help of a loop. 
2. Apply gentle heat by passing the slide over a Bunsen flame for 3 – 4 
times. 
3. Cover the smear with the cover slip. 
4. Leave it for 5 – 10 minutes. 
5. Examine the slide under low(10X) and high power (40X) 
magnifications. 
6. Examine the slide for 15 – 20 minutes for demonstration of shining 
fungal elements. 
 
Results And Interpretations:-   
Different fungi will have different morphological forms (yeasts, cells 
with pseudo hyphae, budding, septate, and aseptate, hyphae, granulesetc) 
which can be clearly seen in a KOH wet mount. 
Interpretation of results should be done by critical analysis of the type, 
size and color of fungal elements which will be different for different fungi. 
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LACTOPHENOL COTTON BLUE (LPCB) 
WET MOUNT PREPARATION:-   
  Tease mount preparation: - 
Procedure: - 
1. Place a drop of LPCB on a clean glass slide. 
2. Remove a small portion of the colony and the supporting agar at a point 
between the centre and periphery and place it in the drop of LPCB. 
3. With a needle, tease the fungal culture first and spread it in the LPCB. 
4. Examine microscopically after giving sufficient time for the structures 
to take up the stain, usually 30 minutes. 
 
Results And Interpretations:- 
     The fungal elements grown should be observed and results interpreted 
depending on the morphology of the hyphae and the spores. 
 
      Different fungi under LPCB wet mount will show different types of 
morphological structures including hyphae and the spores. This should be 
thoroughly differentiated and the fungus identified.  
   Fast growing fungi in case  of slide culture preparation will give satisfactory 
results in 24 – 48 hours. 
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SLIDE CULTURE : - 
Procedure:- 
1. From the petri dish containing sabouraud’s agar cut out one square cm 
block of agar for each slide culture to be inoculated. 
2. With the flat side of a sterile bacteriological loop ( or ) with a sptula, 
place an agar block in the centre of the slide in the slide culture set up. 
3. With a probe, inoculate around the periphery of the agar block, 3 – 4 
fragments of the mould to be cultured. 
4. With forceps, the tips of which have been flamed, place the cover slip 
on the agar block. 
5. With a pipette, thoroughly moisten, but not to excess, the filter paper 
with sterile distilled water. 
    6.  Incubate the slide culture at room temperature. 
    7. Remove the slide culture from the petri dish and dry the bottom of the 
slide with a tissue. 
    8. When growth appears beneath the cover slip, take a slide ,place a drop of 
LPCB on it, and place the cover slip removed from the block on the 
LPCB. 
   9. Place the  slide on the microscope stage and examine.   
      The aerial hyphae including the conidiophores will be seen to grow along 
the undersurface of the cover slip. 
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Results And Interpretations:- 
 Small spore bearing fungi make beautiful permanent mounts, some 
large spore bearing organisms like Microsporumgypsium do not stain as well. 
With the type of hyphae arrangement of conidiophores, staining 
charactierticsetc, the final interpretation of the fungal type can be made. 
 
GERM TUBE TEST 
PROCEDURE 
 Take 0.5 ml of serum in a test tube and add half of a single colony to be 
tested by using a sterile loop, and mix with serum. 
 Incubate the tube at 37o C for a maximum of 11/2 hrs. 
 Place one drop of suspension on to a slide and place cover slips over 
the drop. 
Examine the slide under low (10X) and high power (40X) 
magnifications. 
 
Observations:- 
 Under the microscope , the whole field under the cover slips is 
examined for any cell showing production of germ tube. 
Germ tubes are seen as long tube like projections extending from yeast cells.  
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SABOURAUD’S AGAR MEDIUM FOR PRIMARY ISOLATION OF 
FUNGUS FROM CLINICAL MATERIALS: 
 
PROCEDURE: 
1. Weigh the ingredients 
2. Dissolve the ingredients in water by gentle heating 
3. Make up the volume of the medium to 1 litre. 
4. Adjust the PH to 5.4 
5. Add agar agar. Dissolve the agar by free steaming or by continuous 
stirring by placing the container in a water bath. 
6. Filter through layers of gauze piece. 
7. Distribute in bottles 
8. Sterilize by autoclaving at 8 lbs pressure for 30 minutes. 
9. Cool a part of sterile molten media at an approximate temperature of 
52oC keep remaining media in bottles 
10. Distribute the part of cooled sterile medium in sterile petri dishes with 
sterile precautions’. 
11. Store at 4oC   
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SDA: 
It is a selective medium for cultivation of fungi 
 It  contains  glucose 40g 
 Peptone 10g 
 Agar 20 -30 g 
 Distilled water – 100ml 
It is pate, transparent slope dispensed in large text tubes with Ph 5.4 
 
 
 
INTERPRETATION OF FUNGAL CULTURES 
 
 Inoculated SDA Slants were incubated at 25-30c for minimum of 4 
weeks before discarding as negative. These Slants were inspected daily during 
the first week and twice weekly during the next three weeks for growth. 
 In case of yeasts, identification was done by Grams Stain morphology, 
germ tube test, morphology on cornmeal agar and biochemical tests by 
Standard microbiological techniques as recommended by CLSI. 
 Identification of filamentous fungi was done by preparing lactophenol 
cotton blue mount and studing the morphology of hyphae and conidial 
arrangement. 
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ANTIMICROBIAL TESTING; 
 Antimicrobial testing was done by disc diffusion method, using Kirby-
bauer technique on Muller Hinton agar(High media),using appropriate 
antimicrobial drugs as CLSI guidelines. 
 
 Inoculated suspension, equivalent to a 0.5 Mac Farland Standard, 
incubated at 35+-2°C ambient for 16 to 18 hours. 
 
 Media and discs were tested for quality control using Standard ATCC 
control strains 
 
 The following standard strains were used: 
 1. Staphylococcucaureus-ATCC 25923 
 2. Eschericha coli-ATCC25922 
 3. Klebsiella pneumonia-(ESBL)-ATCC-700603 
 4. Pseudomonas aeuroginosa-ATCC 27853 
  
 The diameters of Zones of inhibition were interpreted according to 
CLSI Standards for each organism. 
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THE PANEL OF ANTIBIOTICS INCLUDED IN THE ANTI 
MICROBIAL SENSITIVITY TESTING FOR GRAM NEGATIVE 
BACILLI WERE; 
 
Antibiotic Disc content in µg 
Diameter of Zone of Inhibition in mm 
Break Points 
Sensitive Intermediate Resistant 
Amikacin 30 
 
15-16 
 
Cefotaxime 30 >26 23-25 
 
Ceftriaxone  
 
20-22 
 
Ceftazidime  
 
18-20 
 
Cortrimoxazole 1.25/23.75 
 
11-15 
 
Ciprofloxacin 5 
 
16-20 
 
Gentamicin 10 
 
13-14 
 
Imipenem  10 
 
22-22 
 
Piperacillin-
Tazobactam  100/10  18-20  
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ANTIMICROBIAL SENSITIITY PATTERN OF GRAM POSITIVE 
AND GRAM NEGATIVE  COCCI 
 
 
Antibiotic 
Disc 
content in    
µg 
Diameter of Zone of Inhibition 
In mm Break Points 
Sensitive Intermedi
ate Resistant 
Amikacin 30 
 
15-16 
 
Ampicillin  10 >17 - 
 
Amoxy-
cillinclavulanic 
acid  
20/10 
 
- 
 
Cortrimoxazole 1.25/23.75 
 
11-15 
 
Ciprofloxacin 5 
 
16-20 
 
Cefoxitin 30 
 
- 
 
erythromycin  15 
 
14-22 
 
vancomycin  30 
 
- 
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DETECTION OF β LACTAMASE ENZYMES PRODUCTION IN 
GRAM NEGATVE BACILLAI 
 
A. EXTENDED SPECTRUM β LACTAMASES (ESBL) DETECTION 
METHODS 
1. Screening method. 
 An inoculum of 0.5 McFarland Standard turbidity was prepared in a 
nutrient broth from  isolated colonies taken from 18-24 hour agar plates. A 
sterile swab was dipped into the nutrient broth and inoculated into a dried and 
sterile Muller-Hinton Agar (MHA) plate. The antibiotics were applied to the 
surface of the plate after 3-5 minutes of inoculation. The discs were pressed 
firmly against the surface of the plate and distributed evenly so that the 
minimum distance was 24mm. 
 If any of the isolates had zone of inhibition for third generation 
cephalosporins - Ceftazidime 30µg≤22mm, Aztreonam 30µg ≤ 27mm, 
Cefotaxime 30µg ≤ 27mm and  Cefriaxone 30 ≤ 25mm (ESBL breaking point) 
as well as strains which were resistant were taken as screen positive for ESBL. 
 All strains found to be ESBL Screen test positive were subject to 
further confirmation by CLSI. 
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2.PCDDT -Phenotypic Confirmatory Disc Diffusion Test 
 The Strains screened positive for ESBL production were tested by 
PCDDT for Confirmation, Discs of Ceftazidime (CAZ-30µg) and Ceftazidime 
with Clavulanic Acid (CAC-30/10µg) and Ceftaxime (CTX-30µg) and 
Cefotaxime-Clavulanic Acid (CTX/C-30/10µg) were dispersed at a minimum 
distance of 24mm on an MHA agar plate inoculated with the lawn culture of 
the isolate Screened positive for ESBL production and  incubated aerobically 
at 370C overnight. If there was an increase in zone size by≥5mm with 
Ceftozidime/Clavulanic acid and Cefotaxime/Clavulanic acid in comparision 
to Ceftazidime or Cefotaxime alone, then the strain of Enterobactericeae was 
confirmed to be ESBL producer. 
 E .coli-ATCC 25922 and KlebsiellaPneumoniae ATCC-700603 were 
taken as controls for phenotypic confirmatory test for ESBL. 
 
3. Double Disc Diffusion Synergy Test 
 In this test discs of third generation Cephalosporins and Augmentin 
(20µg/10µg) were kept 30mm apart from centre to centre on inoculated 
Muller-Hinton Agar (MHA). 
 A clear extension of the edge of the inhibition zone of Cephalosporin 
towards Augmentin disc was interpreted as positive for ESBL production. 
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B.Amp C –Β-LACTAMASE DETECTIONS; 
1. Screening Method 
 A 0.5 McFarland of the test isolate was swabed on MHA plate  and disc 
of Cefotaxime (30µg), Ceftazidime(30µg) were placed adjacent to Cefoxitin 
(30µg) disc at a distance of 20mm from each other. 
 After incubation, isolates showing blunting of Ceftazidime or 
Cefotaxime zone of inhibition adjacent to cefoxitin disc or showing reduced 
susceptibility to either of the above drugs and cefoxitinwere  considered as 
screen positive and selected for detection of AmpC β lactamases. 
 
2.AmpC Disc Test; 
 A lawn culture of E.coli ATCC 25922 were prepared on MHA plate. 
Sterile disc (6mm) were moistened with sterile saline and inoculated with 
several colonies of test organism. The inoculated disc was then placed beside a 
Cefoxitin disc (almost touching) on the inoculated plate. The plates were 
incubated overnight at 35°C. A positive test appeared as a flattening or 
indentation of the of cefoxitin inhibition zone in the vicinity of the test disc. A 
negative test had an undistorted zone. 
 
 
 
 
73 
 
C.METALLO-β-LACTAMASES (MBL) DETECTION METHODS; 
1.Imipenem-EDTA disc diffusion method; 
 A 10µg imipenem disc containing 750 mg of EDTA solution was used. 
The inhibition zone with imipenem –EDTA disc were ≤14 mm for the MBL- 
negative isolates and ≥17mm for MBL positive isolates. 
 
 Imipenem disc diffusion method was employed as a screening test to 
select suspected MBL strains showing resistance to imipenem which were 
further confirmed by imipenem –EDTA combined disc method and imipenem-
EDTA double disc synergy test. 
 
2. Imipenem-EDTA Combined disc Test 
 A lawn culure of test isolates was prepared. After allowing it to dry for 
five minutes, two imipenem dics, one with 0.5 EDTA and the other a plain 
imipenem disc, were placed on the surface of agar plates approximatetly 
30mm apart. 
 
 The plates were incubated overnight at 37OC. An increase in zone 
diameter of ≥7mm around imipenem+EDTA disc in comparision to imipenem 
disk alone indicated production of MBL. 
74 
 
DETECTION OF METHICILLIN RESISTANCE IN 
STAPHYLOCOCCUS AUREUS; 
 
1.Disc diffusion method; 
 Colonies isolated from agar culture plates were suspended directly into 
broth to reach 0.5 McFarlands Standard. 
 A lawn culture of the staphylococcal isolates wsa made on the MHA 
plate and 30µg Cefoxitin discs was placed on the surface of  lawn culture and 
incubated at 35c for 24 hours in ambient air. 
 According to CLSI criteria, isolates showing inhibition zone diameter 
≥22mm were considered as methicillin sensitive strains and those that show 
inhibition zone diameter ≤21mm were considered as methicillin resistant 
zones. 
 Routine disc diffusion procedure with Cefoxitin disc (30µg) followed 
by confirmatory testing should be done using minimum inhibitory 
concentration(MIC) either broth microdilution 
 
2. E-test. 
Vancomycin E-test strips; 
Have been used alone or in combination with a teicoplanin strip (Macro 
E test or MET) 
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RESULT 
 This study was conducted in Thoracic Medicine Ward of Thanjavur 
Medical College Hospital. The total number of patients admitted during the 
study period were 980 out of which 100 patients who fulfilled the study 
criteria were taken for this study. 
TABLE 1 
AGE AND SEX WISE DISTRIBUTION OF PATIENTS 
Age No of Patients Percentage 
<20 5 5 
21-40 years 21 21 
41-60years 47 47 
>60 years 27 27 
Chart 
5
21
47
27
0
5
10
15
20
25
30
35
40
45
50
<20 21-40 years 41-60years >60 years
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TABLE 2 
SEX DISTRIBUTION OF PATIENTS 
Sex No of Patients Percentage 
Male 46 46 
Female 54 54 
 
Chart 
Male, 46
Female, 54
Male Female
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TABLE 3 
AGE AND SEX GROUPS UNDER STUDY 
 
<20 years 21-40 years 41-60years >60 years Total 
n % N % N % n % n % 
Male 1 20.0% 7 41.2% 21 42.0% 17 60.7% 46 46.0% 
Female 4 80.0% 10 58.8% 29 58.0% 11 39.3% 54 54.0% 
Total 5 100.0% 17 100.0% 50 100.0% 28 100.0% 100 100.0% 
Statistical 
inference X
2
= 4.283 Df=3    p=0.233>0.05 Not Significant 
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TABLE 4 
OCCUPATION AS RISK FACTORS AMONG COPD PATIENTS 
 COPD N=100 
No % 
1 Bio gas inhalation 20 41% 
2 Cotton mill worker 14 29% 
3 Agricultural worker 10 20% 
4 Rice mill worker 5 10% 
 
Bio gas inhalation was associated with 41% of COPD, 29% in cotton 
mill worker 
41%
29%
20%
10%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
Bio gas inhalation Cotton mill worker Agricultural worker Rice mill worker
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TABLE 5 
RISK FACTORS ASSOCIATION OF COPD SMOKING AND ALCOHOL 
NO  COPD No % 
1 Smoking 23 26.45 
2 Non Smoking 77 88.55 
3 Smoking and Alcohol 15 17.25 
  115  
 
TABLE 6 
ANALYSIS OF CAUSES OF COPD IN PATIENTS 
NO  COPD 
No % 
1 Smoking 23 31 
2 Bio gas inhalation 20 27 
3 Smoking and Alcohol 15 21 
4 Agricultural worker 10 14 
5 Cotton mill worker 14 7 
 
Charts 
31
27
21
14
7
0
5
10
15
20
25
30
35
Smoking Bio gas inhalation Smoking and Alcohol Agricultural worker Cotton mill worker
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 TABLE 7  
CASE DISTRIBUTION AMONG COPD PATIENTS 
NO TYPE NO % 
1 Chronic bronchitis 60 60 
2 Emphysema 15 15 
3 Bronchial asthma 25 25 
 
Chronic bronchitis was the most common condition in COPD 
Chronic bronchitis, 60
Emphysema, 15
Bronchial asthma, 25
Chronic bronchitis Emphysema Bronchial asthma
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TABLE 8 
SYMPTOMS ANALYSIS IN COPD 
NO SYMPTOMS COPD 
No % 
1 Shortness of breath 40 35 
2 Cough 35 31 
3 Cough with sputum production 30 26 
4 Chest pain 5 4 
5 Fever 5 4 
 
Increased level of Cough with expectoration and breathlessness were 
the commonest symptoms among patients with COPD 
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TABLE 9 
COMORBID ILLNESS IN COPD 
NO Co morbid illness COPD 
No % 
1 DM 20 57 
2 H T 10 29 
3 CAD 5 14 
 
DM was the most common Co morbid illness followed by Hyperion and CAD 
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TABLE 10 
COMPLICATIONS IN COPD PATIENTS 
NO Complications COPD 
No % 
1 Corpulmonale 6 46 
2 Respiratory failure 4 31 
3 Cardiac failure 3 23 
 
Corpulmonale was the most common complication followed by 
respiratory failure 
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TABLE 11 
PATHOGENS ISOLATED FROM COPD PATIENTS 
NO Pathogens Isolated COPD 
No % 
1 Bacteria 43 30 
2 Fungi 18 13 
3 Polymicrobial 10 7 
 Total pathogens isolated 71 50 
 
TABLE 12 
TYPE AND COMBINATION OF PATHOGENS ISOLATED 
NO Type of Pathogens No of cases N=100 % 
1 Insignificant Growth 28 28 
2 Monobacterial 43 43 
3 Polymicrobial 10 10 
4 Bacterial and Bacterial 7 7 
5 Bacterial and Fungal 3 3 
 
43% showed pure bacterial growth, mixed infection was seen in 10% of 
the cases 
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TABLE 13 
BACTERIAL PATHOGENS ISOLATED FROM COPD PATIENTS 
NO Pathogens Isolated No of Isolated % 
1 Klebsiella 16 37 
2 Pseudomonas aeruginosa 12 27 
3 Staphylococcus aureus 6 14 
4 Escherichia coli 5 11 
5 Moraxella Catarrhalis 1 2 
6 Acinetobacter 4 9 
Chart  
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TABLE 14 
BACTERIAL PATHOGENS ISOLATED FROM COPD PATIENTS 
GRAM NEGATIVE BACTERIA 
 
NO Pathogens Isolated No of Isolated % 
GRAM NEGATIVE BACTERIA 
1 Klebsiella 16 43 
2 Pseudomonas aeruginosa 12 32 
3 Escherichia coli 5 14 
4 Acinetobacter 4 11 
5 Moraxella Catarrhalis 1 10 
GRAM POSITIVE BACTERIA 
1 Staphylococcus aureus  6 60 
2 MRSA 3 30 
 
TABLE 15 
Fungal Pathogens Isolated FROM COPD PATIENTS 
NO Pathogens Isolated No of Cases % 
1 Candida  albicans 9 41 
2 Aspergillus  niger 5 23 
3 Aspergillus flavus 4 18 
4 Aspergillus fumigtius 4 18 
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TABLE 16 
DRUG RESISTANCE MECHANISM AMONG THE PATHOGEN 
ISOLATED FROM COPD PATIENTS 
NO Pathogens n=43 No of Drug 
resistant isolation 
% 
1 Klebsiella pneumoniae      n(16) 9 28 
2 ESBL 7 22 
3 Amp C&β Lactamase 4 13 
4 Pscudomonas aeruginosa n=(12)  Multi drug resistant 6 19 
5 Acinetobacter n=(4) Multi drug resistant 2 6 
6 Moraxella Catarrahalis n=(1) 1 3 
7 Methicillin resistant Staphylococcus aureas 3 9 
 
TABLE 17 
ANTIMICROBIAL SENSITIVITY PATTERN OF GRAM POSITIVE 
BACTERIA  
 
NO Antibiotics Staphylococcus 
aureas 
% 
1 Amikacin 1 8 
2 Amoxycillin Clavulanic 
acid 
0 0 
3 Ciprofloxacin 2 17 
4 Erythromycin 1 8 
5 Cefotaxime 2 17 
6 Vanconycin 6 50 
89 
 
 
TABLE 18 
ANTIMICROBIAL SENSITIVITY PATTERN OF GRAM NEGATIVE 
BACILLI 
 
Antibiotics E.coli n=5 
Klebsiella 
pneumonia 
n=16 
Pseudomonas 
n=12 
Acinetobacter 
n=4 
Amikacin 2 40 12 75 8 66.7 2 50 
Ceftazidime -  4 25 2 16.7 2 50 
Cefotaxime 1 20 4 25 3 25 2 50 
Ciprofloxacin 1 20 10 62.5 8 66.7 2 50 
Gentamycin 1 20 8 50 8 66.7 1 25 
Imipenem 5 100 16 100 12 100 4 100 
Piperacillin- 
Tazobactam - 100%       
 
TABLE 19 
DETECTION OF ESBL PRODUCERS AMONG THE ISOLATES 
 
Pathogens 
No of Positive Isolated 
Screening Test DDST PCDDT 
N % n % n % 
Klebsiella 
pneumonia 
n=16 
9 56.25 7 43.75 7 43.75 
E.coli n=5 2 40 2 40 2 40 
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TABLE 20 
DETECTION OF AMPC PRODUCERS AMONG THE ISOLATES 
 
Pathogens 
No of Positive Isolates 
Screening Test DDST PCDDT 
N % N % n % 
Klebsiella 
pneumonia 
n=16 
9 42.8 7 58 7 58 
Pseudomonas 
n=12 
8 38 4 33 4 33 
Acinetobacter 
n=4 
4 19 1 8 1 8 
 
TABLE 21 
DETECTION OF MBL PRODUCERS AMONG THE ISOLATES 
Antibiotics Pseudomonas n=4 Acinetobacter n=4 
Senstive Resistant Senstive Resistant 
Imipenem 12(100%) - 4(100%) - 
Imipenem 
EDTA 12(100%) - 4(100%) - 
 
TABLE 22 
DETECTION OF METHICILLIN RESISTANCE AMONG THE 
ISOLATES 
Methods Staphylococcus aureas n=(6) 
Disc diffusion method 3 50 
MIC detection 3 50 
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DISCUSSION 
 This prospective study was conducted at Thanjavur Medical College 
Hospital in association with the Department of Thoracic Medicine at 
Thanjavur Medical College, Thanjavur. The study population consisting of 
100 patients with signs of symptoms of COPD patients were selected 
according to GOLD Criteria9 
 The study population included in the COPD patients were in the age-
group of 18-80 years. The majority of  COPD patients in our study were in the 
age-group of 40-60 years (47%) Table – I 
 This can be explained by the fact that COPD has the highest prevalence 
after fifth or sixth decade of life. As age advances, the physiological decrease 
in lung function is accentuated because of the expression of deterioration in 
host defences at the bronchial mucosal level in patients with advanced age. 
This study observation correspond to the study of Jorg et al. 
 In our study COPD was more common among smokers. More than 
50% in males were seen and were exposed more to outside environment. This 
was similar to the study done by Arora et al. Smoking causes an inflammatory 
process in the airways. 
Smoking followed by biogas inhalation is a risk factor in female patients. 
There was a female predominance of 54% over males in COPD Among 
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women exposure to indoor air pollution was an important risk factor who were 
exposed to biomass fuel and air pollution resulting from the burning of wood 
and other biomass fuel –wood, charcoal, other vegetable matter and animal 
dung was also a risk factor in COPD. In our study 41% of biogas inhalation 
was seen in female patients. This study corresponds to the study of Lopez                 
et al. 
Occupation as a risk factor of COPD was  found in 29% of cotton mill 
worker, in 20% agricultural workers and 10% of rice mill workers  in this 
study. 
Higher prevalence of chronic bronchitis was seen in this study as 
compared to emphysema86 
Comorbidities –diabetes was found in 20% of COPDpatients.This was 
corresponding to a study done by Holguin 87 
Complications were observed in COPD patients. Corpulmonale was the 
most common complication (46%) followed by respiratory failure (31%)  
(Adil, Shujaat, et al) 
 Sputum was the most common sample collection processed from 
patients with COPD. Out of 100 samples 60% showed culture positivity and 
40% showed culture negativity. Similar to the study of Groenewegan et al.              
A similar observation was made by Arora et al in which culture positive in 
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>60% of cases among all respiratory samples. Purulent sputum yielded 
positive bacterial culture as compared to nonpurulent sputum which correlates 
with the study done by Chawla K et al. 
A mono Bacterial growth was identified in 43% while polybacterial 
growth was observed in 10% (Table 12). This is similar to the study of Gerard 
Rakesh et al. 
 In our study, the bacterial and fungal isolates from the COPD patients 
of varied etiology were isolated. 
BACTERIAL ISOLATES 
(1) Gram negative bacteria were the commonest organisms in the 
respiratory sample in patients with COPD. 80% as compared to 20% 
gram positive bacteria (Niederman Michael 2000) 92 
(2) Niderman and Michael have mentioned in their studies that gram 
negative bacteria was the commonest bacteria isolated. 
(3) Among the gram negative organisms klebsiella pneumonia 37% was 
the common bacteria in our study, followed by pseudomonas 
aeruginosa 27%, Esherichiacolli 11% and acinetobacter 9%. This is 
similar to  the study by Chawla et al and Mahebi et al 88,89 
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(4) A study done by Eller jong et al which states the prevalence of 
pseudomonas with acinetobacter increases in patients with declining 
lung function. This present study observation corresponds to the study 
by N Roche et al. 
(5) Polymicrobial infection among COPD patients was found in 10% of 
culture positive cases. This polymicrobial infection was seen with 
klebsiella pneumonia and pseudomonas aeruginosa followed by Ecoli 
and acinetobacter.  Similar study by Gerard Rakesh et al reported 
polymicrobial infections in 6 cases of klebsiella pneumonia& 3 cases of 
pseudomonas aeruginosa and 3 cases of acinetobacter and 
staphylococcus which was similar to our findings. 
 
FUNGAL ISOLATES 
1. Fungal infections occur most often with other pathogens in immuno 
compromised patients. In the present study 22 fungal pathogens were 
isolated. In our study candida species 41 %, Aspegillus niger 23%, 
Aspegillus flavus18% and Aspegillusfumigatus18% were isolated. 
2. These patients had repeated isolations of the above mentioned fungi 
with the sputum sample collected on three consecutive days. The gram 
stained smears also revealed pseudophyphae with yeast cells.  Shanker 
et al93 reported candida  species in 80% of their isolates. 
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3. Shivananda94 in his study in 1992 on 825 patients with pulmonary 
infection  found 15% isolates were Aspergillus species.95 Pulmonary 
Aspegillosis in 36 samples were documented  by Geethalakshmi et al.95 
 
POLYMICROBIAL ISOLATES 
Polymicrobial isolates were found to be common in  COPD patients. 
Klebsiella pneumonia, pseudomonas aeruginosa, acinetobacter and 
staphylococcus aureus were found to be more. This was similar to the study of 
Shanker et al.  
 
ANTIBIOTIC SUSCECTIBILITY 
 
1) The antibiogram was performed for various isolates and were analyzed. The 
commonest gram negative bacilli isolated from respiratory samples of 
COPD patients was klebsiella pneumonia that showed 75% sensitivity to 
amikacin, 62.5% sensitivity to ciprofloxacin. 
- 22% were extended spectrum β lactamase producing strains. 
- Similar study was observed by Gerard Rakesh et al96. 
- Among the mechanisms of resistance to third generation 
Cephalosprin sproduction of ESBL and AmpC β lactamases are the 
most common. 
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- Out of the 16 isolates of klebsiella  spp screened for ESBL 
production 56.25% found to be positive. By phenotypic confirmatory 
disc diffusion method 43.75% were confirmed as ESBL producers. 
- Among the 16% isolates 42.8% were found to be AmpC producers. 
Hemalatha et al also showed AmpC production in 47.3% of    
isolates 97. 
 
2)  Out of 12 isolates,  pseudomonas aeruginosawas 66.7% sensitive to 
amikacin and ciprofloxacin were screened AmpC positive. 33%  isolates 
were found to be AmpC producers by AmpC disc test. The overall rate of 
multidrug resistance in pseudomonas aeruginosa was 75%. However no 
isolate was found to be metallo-beta lactamase producers. This resistance 
pattern was similar to the study done by Chawla et al who stated 60% 
resistance of pseudomonas aeruginosa to third generation cephalosporins98 
- Nonfermenter acinetobactor baumannii isolated from COPD cases 
showed 6% of multi drug resistant strains and showed a significant  
level of resistance to third generation cephalosporins and 8% were 
AmpC producers. This implies that acinetobactor baumannii was also 
one of the important drug resistant pathogens isolated from cases of 
COPD. This study is similar to the study by Wang Huei Sheng et al in 
2013 where 15.3% of acinetobactor baumannii isolated from COPD 
patients were AmpC producers. 
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- All gram negative isolates in the study were found to be sensitive to 
imipenem, Khanfar et al in their study also showed all isolates were 
imipenem sensitive99. 
- The prevalence of carbapenamase producers varies depending upon 
clinical environment and use of inappropriate empirical antibiotic 
therapy. 
- The most common gram positive isolates from respiratory samples in 
COPD patients in our study was staphylococcus aureus. 
- 50% isolates of staphylococcus were found to be methicillin resistant. 
This indicates that the use of inadequate antibiotics during empirica 
ltherapy of longer duration of hospitalization may selectively enhance 
the growth of the drug resistant pathogen. A study conducted by 
INSAR group stated that the prevalence of MRSA in India varies from 
25% in western part of India to 50% in South India. (Sangeetha et al) 
(2010). This study statement correlates with the present study. Chawla 
k et al in their study observed that 50% of Staphylococcus isolates were 
MRSA. All the MRSA isolates in our study were sensitive to 
vancomycin.  
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SUMMARY 
 
This study was conducted at the  Thanjavur Medical College Hospital. 100 
patients  admitted in Thoracic Medical Unit with various clinical presentations 
were studied . 
 The majority of the COPD patients were in the age group 40-60 years. 
 Among the patients in the study group, 75 showed  symptoms of 
COPD. 
 Sputum was the common specimen    
 Chronic bronchitis  was the common condition in COPD patients. 
 Chronic bronchitis of 15 patients were emphysema. 
 Smoking was associated with 60% risk among COPD patients. 
 Biogas inhalation was associated with COPD. 
 Most common symptoms were shortness of breath and cough with 
expectoration. 
 Complications were observed in15%   among which Corpulmonale was 
the most common complication followed by respiratory failure. 
 Bacterial and fungal pathogens were isolated. Among the bacteria, 
gram negative bacilli  klebsiella pneumoniae was the most commonly 
isolated bacilli 
 Among the fungal pathogens  identified, Candida and Aspergillus spp 
were the common one in this study. 
 Mycoplasma was not isolated  in this study. 
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CONCLUSION 
 
 This study on 100 patients admitted in Thoracic Medical Unit, 
Thanjavur Medical College, Thanjavur was conducted in order to study the 
risk factors of COPD, etiological agents, antibacterial susceptibility pattern of 
the isolates and prevalence of multi drug resistance among the isolates. 
 Exacerbations mostly of infective etiology are a frequent cause of 
morbidity in COPD patients. So this study has been taken to analyze the 
bacterial and fungal profile with their sensitivity pattern. Bacterial infections 
are the most common reason for exacerbations, in our study among which 
Klebsiella pneumoniae and pseudomonas aeruginosa were the commonest. 
 Purulent sputum sample is a good and easy to obtain, that provides 
preliminary idea about the pathogen, thereby helping in selecting antibiotic for 
empirical antibiotic therapy. 
 Hence the choice of empiric antibiotics should be based on local 
pathogens prevalence and antibacterial susceptibility and on identification of 
patients with selected clinical parameters at high risk of developing infections 
caused by multidrug resistant micro organisms. Hence periodic isolation and 
identification of resistant status of pathogens responsible for COPD will be 
helpful in formulating the  antibiotic policy.  
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 Continuous surveillance to detect the resistant strains, strict guide lines 
for the antibiotic therapy and the implementation of infection control measures 
reduce the increasing burden of antibiotic resistance. 
 A knowledge of the resistant pattern of ESBL producing 
Enterobactericiae in the geographical area will help us to formulate 
appropriate treatment protocol which will be of immense use in producing 
mortality and morbidity.  
 Along with conventional antibiogram, routine ESBL testing should be 
done which reduces the volume of antibiotics and development of resistance to 
antibiotic. 
 
 
 
 
 
 
 
 
S.NO
AGE SEX IP NO SAMPLE DIAGNOSIS ISOLATES
CO MORBIDITY AND 
COMPLICATIONS
SMOKER BIO MASS FUEL
ARICULTU
RAL 
WORKER
COTTON 
MILL 
WORKER
1 60 F 443 sputum COPD/AE Escheria Coli NIL - Biomass - -
2 60 M 54537 sputum Chronic Bronchitis Klebsiella pneumoniae NIL - - AW -
3 60 F 2234 sputum BA/AE Klebsiella pneumoniae NIL smoker alcoholic Biomass - -
4 50 M 3208 sputum COPD/AE - NIL smoker alcoholic Biomass - -
5 36 M 3028 sputum Chronic Bronchitis Klebsiella pneumoniae NIL smoker alcoholic Biomass - -
6 65 F 1649 sputum BA/AE Escheria Coli HT - Biomass - -
7 35 F 4330 sputum Chronic Bronchitis Pseudomonas 
aeruginosa NIL - Biomass - -
8 47 F 4067 sputum Chronic Bronchitis NF NIL - Biomass AW -
9 65 F 4366 sputum COPD / AE Pseudomonas 
aeruginosa NIL - Biomass - -
10 60 F 4566 sputum Chronic Bronchitis - DM smoker alcoholic - - -
11 53 F 4594 sputum BA/AR - NIL - Biomass - -
12 56 F 5477 sputum COPD Pseudomonas 
aeruginosa NIL - Biomass - -
13 18 F 5233 sputum Chronic Bronchitis - - - - - -
14 45 F 6484 sputum COPD Aspergillus flavus RVF/(CF) - Biomass - -
15 45 M 6114 sputum COPD - - smoker alcoholic - - CMW
16 32 M 6084 sputum Chronic Bronchitis - HT Alcoholic - - CMW
S.NO
AGE SEX IP NO SAMPLE DIAGNOSIS ISOLATES
CO MORBIDITY AND 
COMPLICATIONS
SMOKER BIO MASS FUEL
ARICULTU
RAL 
WORKER
COTTON 
MILL 
WORKER
17 63 M 8626 sputum COPD Staphylococcus HT - - - RICE MILL WORKER 
18 40 M 8798 sputum BA Staphylococcus - smoker  - CMW
19 75 M 9837 sputum COPD Klebsiella pneumoniae - - - - CMW
20 62 M 11010 sputum COPD/AE Pseudomonas 
aeruginosa - - - - CMW
21 57 M 9003 sputum COPD - DM - Biomass -
22 46 M 11173 sputum COPD/AE Aspergillus flavus - alcoholic smoker Biomass -
23 57 M 11198 sputum BA/AE Escheria Coli - - - -
24 60 M 12327 sputum BA/AE Acinetobacter baumannii - - - -
25 60 M 10439 sputum Chronic Bronchitis Pseudomonas 
aeruginosa - - - AW
26 35 Metc 15073 sputum Chronic Bronchitis - - alcoholic smoker - - RICE MILL WORKER 
27 37 F 16075 sputum BA/AR - - - - - CMW
28 25 F 15258 sputum Chronic Bronchitis - - - Biomass - -
29 45 F 12726 sputum COPD Acinetobacter baumannii - - - AW
30 57 F 16465 sputum BA/AR Pseudomonas 
aeruginosa - - - -
RICE MILL 
WORKER 
31 43 F 16843 sputum BA/AE Escheria Coli - - Biomass -
32 18 F 16850 sputum Chronic Bronchitis Aspergillus niger - - - -
S.NO
AGE SEX IP NO SAMPLE DIAGNOSIS ISOLATES
CO MORBIDITY AND 
COMPLICATIONS
SMOKER BIO MASS FUEL
ARICULTU
RAL 
WORKER
COTTON 
MILL 
WORKER
33 60 F 15572 sputum Chronic Bronchitis - HT/DM - - - 0
34 56 F 17954 sputum COPD Acinetobacterbaumannii - - Biomass -
35 36 F 17699 sputum COPD - - - Biomass -
36 42 M 18536 sputum COPD/AE Candida Pseudomonas - smoker alcoholic - AW -
37 56 M 18576 sputum COPD - - smoker  - - STEEL MILLWORKER 
38 55 F 18872 sputum BA/AE Pseudomonas 
aeruginosa - - - AW
39 49 M 19694 sputum COPD/AE - - Betal Leaf chewer - STEEL MILLWORKER 
40 52 M 20706 sputum COPD/AE - - smoker - AW
41 44 F 20412 sputum COPD Acinetobacter baumannii - - Biomass
42 75 F 20500 sputum BA/AE - - - Biomass -
43 54 Metc 22125 sputum COPD - - smoker -
44 75 M 26734 sputum Chronic Bronchitis - - - - -
45 35 F 22131 sputum BA / AE - - - Biomass -
46 23 F 21999 sputum COPD Aspergillus niger - - Biomass -
47 47 F 138433 sputum COPD Pseudomonas 
aeruginosa - - - -
48 40 F 24637 sputum COPD Candida Pseudomonas - - - -
S.NO
AGE SEX IP NO SAMPLE DIAGNOSIS ISOLATES
CO MORBIDITY AND 
COMPLICATIONS
SMOKER BIO MASS FUEL
ARICULTU
RAL 
WORKER
COTTON 
MILL 
WORKER
49 15 F 24051 sputum COPD Candida - - - -
50 34 F 24635 sputum COPD Pseudomonas 
aeruginosa - - - -
51 37 F 25848 sputum COPD - - - - -
52 27 F 24896 sputum COPD - - - Biomass -
53 45 F 25858 sputum COPD Pseudomonas 
aeruginosa - - Biomass -
54 42 M 25073 sputum Chronic Bronchitis - - Biomass -
55 72 F 25500 sputum COPD - CAD - - AW
56 61 M 25272 sputum COPD - - smoker - -
57 54 M 26316 sputum COPD / AE - - - - -
58 70 M 26025 sputum COPD Pseudomonas 
aeruginosa DM smoker alcoholic Biomass -
59 49 F 28023 sputum COPD - - - Biomass -
60 60 F 27335 sputum COPD - CAD - Biomass -
61 46 F 20224 sputum COPD - Allergic disorder - - AW
62 56 M 29130 sputum COPD - HT/DM - - - RICE MILL WORKER 
63 18 M 30368 sputum BA/AE - - - - - -
64 52 F 29432 sputum COPD Staphylococcus DM - Biomass -
S.NO
AGE SEX IP NO SAMPLE DIAGNOSIS ISOLATES
CO MORBIDITY AND 
COMPLICATIONS
SMOKER BIO MASS FUEL
ARICULTU
RAL 
WORKER
COTTON 
MILL 
WORKER
65 65 M 31496 sputum COPD/AE - Cardiac failure Smoker - - COTTON MILL WORKER
66 82 M 31158 sputum COPD/AE Staphylococcus Respiratory failure - - - COTTON MILL WORKER
67 70 F 32069 sputum COPD/AE Staphylococcus DM Biomass -
68 40 M 32004 sputum COPD - DM smoker - - COTTON MILL WORKER
69 61 M 33816 sputum COPD/AE - DM smoker - AW
70 61 M 33080 sputum COPD/AE - DM smoker - - RICE MILL WORKER 
71 20 F 32273 sputum Acute Severe Asthma - Allergic disorder - -
72 65 F 32829 sputum COPD - DM /HT - - COTTON MILL WORKER
73 55 M 32830 sputum COPD Pseudomonas 
aeruginosa DM / Corpulmonale - AW
74 78 M 31926 sputum COPD - Corpulmonale smoker alcoholic - AW
75 45 M 31696 sputum Chronic Bronchitis Staphylococcus HT smoker alcoholic -
76 43 M 33269 sputum Chronic Bronchitis - HT smoker alcoholic - AW
77 61 M 33592 sputum Chronic Bronchitis - DM smoker - cotton mill 
worker
78 63 F 33485 sputum COPD /AE - smoker - AW
79 60 M 33268 sputum COPD - HT -
80 80 F 31905 sputum COPD Pseudomonas 
aeruginosa Corpulmonale - AW
S.NO
AGE SEX IP NO SAMPLE DIAGNOSIS ISOLATES
CO MORBIDITY AND 
COMPLICATIONS
SMOKER BIO MASS FUEL
ARICULTU
RAL 
WORKER
COTTON 
MILL 
WORKER
81 66 F 50352 sputum COPD/AE Klebsiella pneumoniae DM/AR Smoker - AW
82 50 F 49970 sputum COPD Staphylococcus DM/AR smoker - AW
83 70 M 49758 sputum COPD - Respiratory failure - AW
84 45 M 49988 sputum COPD /AE - Corpulmonale smoker - AW
85 28 M 50994 sputum BA - Allergic disorder -
86 68 M 51006 sputum COPD / AE Pseudomonas 
aeruginosa
Corpulmonale / 
HT/DM smoker - AW
87 60 F 51235 sputum COPD - Corpulmonale / HT/DM - - AW
88 65 F 57278 sputum COPD - - - - AW
89 65 F 49629 sputum COPD Pseudomonas 
aeruginosa - - - AW
90 60 F 49738 sputum Chronic Bronchitis - Respiratory failure - Biomass AW
91 60 M 50978 sputum COPD Klebsiella pneumoniae Cardiac failure smoker  Alcoholic -
steel mill
worker
92 70 M 53042 sputum COPD / AE Klebsiella pneumoniae - smoker  Alcoholic -
93 59 M 53116 sputum COPD/AE Klebsiella pneumoniae - smoker  Alcoholic -
94 50 M 54531 sputum COPD Klebsiella 
pneumoniae
- -
95 70 M 53328 sputum COPD/AE - CAD smoker - CMW 
96 70 M 53328 sputum COPD Klebsiella pneumoniae
Cardiac failure 
DM/HT Betal Leaf chewer - AW
S.NO
AGE SEX IP NO SAMPLE DIAGNOSIS ISOLATES
CO MORBIDITY AND 
COMPLICATIONS
SMOKER BIO MASS FUEL
ARICULTU
RAL 
WORKER
COTTON 
MILL 
WORKER
97 77 METE 51697 sputum COPD Klebsiella pneumoniae corpulmonale Smoker -
98 30 M 54202 sputum BA/AE Klebsiella pneumoniae - smoker alcoholic Biomass
99 56 F 54162 sputum COPD Pseudomonas 
aeruginosa - Biomass
100 57 M 53557 sputum Chronic Bronchitis - HT/DM smoker alcoholic - CMW 
APPENDIX – I 
 
ABBREVIATION 
 
ATS   American Thoracic study 
AECOPD   Acute exacerbation of Chronic obstructive pulmonary Disease 
ATCC   American  Type Culture Collections 
CLSI                         Clinical &Laboratory Standards Institute 
COPD   Chronic Obstructive Pulmonary  Disease 
 DDST                       Double Disk Diffusion Synergy Test 
ESBL                        Extended Spectrum Beta lactamases 
ERS                          European respiratory Society 
FEV1                        Forced Expiratory Volume 
FVC                         Forced Vital Capacity  
GNB                         Gram–Negative Bacilli  
GPC                          Gram–Positive Cocci 
MDR  Multi Drug Resistance 
         MHA                          Muller Hinton Agar 
MBL                        Metallo  ß - Lactamases 
MIC                          Minimum Inhibitory Concentration 
MRSA                      Methicillin Resistant Staphylococcus aureus 
MSSA                      Methicillin Sensitive Staphylococcus aureus 
 PCDDT                    Phenotypic Confirmatory Disk Diffusion Test  
 
 
 
APPENDIX – II 
1. STAINS AND REAGENTS 
 
Gram Staining: - 
 
a. Methyl violet ( 2%)   10g  Methyl violet in 100ml 
   absolute alcohol in 1 litre of  
distilled watter ( Primary stain) 
b. Gram’s iodine    10g  lodine in 20g KI ( Fixative) 
 
c. Acetone     Decolourizing agent 
 
d. Carbol fuchsin 1%   Secondary stain 
 
 
2. ACID FAST STAIN 
Basic fuchsin  powder     5 g 
Phenol  ( crystalline      25 g    
Alcohol (95% (or) 100% ethanol)   50 ml 
 Distilled Water        500 ml  
 
20% Sulphuric acid 
Conc Sulphuric acid (98%)     250 ml 
 Distilled Water 1L 
 
Methylene Blue      Counter stain 
1 % Methylene        blue 
 
3. 10% KOH 
Potassium hydroxide     10g 
Glycerol     10ml 
Distilled Water    80 ml 
 4. LACTO PHENOL COTTON BLUE STAIN:- 
Lactic acid    20 ml 
Phenol     20 ml 
Cotton blue (dye)   0.5g 
Glycerol    40ml 
Distilled water   20ml 
 
5. DIENE’S STAIN:- 
Methylene blue   2.5 gm 
Azure blue    1.25 gm 
Maltose    10.0 gm 
Na2 Co3    0.25 gm 
Distilled water   100ml 
 
B.MEDIA USED 
 
 
1. MAC CONKEY AGAR 
 
Peptone     20g  
Sodium taurocholate    5g  
Distilled Water      1ltr 
Agar         20g 
2% neutral red in 50% ethanol   3.5ml 
10% lactose solution     l00mI 
 
Dissolve peptone and taurocholate in water by heating. Add agar and 
dissolve it  in steamer.  Adjust pH to 7.5. Add lactose and neutral red shake well 
and mix. Heat in free steam (100°C) for 1 hour, then autoclave at 115°C for 15 
minutes. 
 
 2. BLOOD AGAR (5%SHEEP BLOOD AGAR) 
 
Peptone     l0g   
Nacl        5g  
Distilled water                                1Ltr 
Agar                                                10g        
 
3. SABOURAUD’S DEXTROSE AGAR 
Dextrose     40g  
Peptone       l0g  
Agar      20g 
Distilled water     l000ml  
pH=5.5 
 
4. PPLO AGAR 
Peptone        10g 
Meat infusion agar  #  250 
Sodium Chloride    5g 
Final Ph (at 25°C)-7.8 ± 0.2  
 
5. MUELLER-HINTON AGAR 
 
Beef infusion                            300ml 
Caesein hydrolysate                   17 .5g    
Starch                                      1.5g 
Agar                                       10g 
 Distilled water                   1ltr 
 pH=7.4 
Sterilise by autoclaving  at 121° C for 20mins 
 
 C.MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION 
 
1. Oxidase Reagent 
 
Tetra  methyl  p-phenelene diamine  dihyrochloride-  1%   aqueous solution. 
2. Catalase 
 
3% hydrogen peroxide 
 
3. Indole test 
 
Kovac’s reagent 
Amyl or isoamyl alcohol                      150ml  
Para dimethyl amino benzaldehyde 10g  
Concentrated hydrochloric acid             50ml 
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in 
small quantities and store in the refrigerator. Shake gently before use. 
 
4. Christensen’s Urease test medium 
 
Peptone                                                     1g  
Sodium chloride                                         5g 
Dipotassium hydrogen phosphate              2g  
Phenol red                                                  6ml  
Agar                                                            20g  
Distilled water                                          1ltr 
10% sterile solution of glucose                   l0ml 
Sterile 20%urea solution                             l00ml 
 
 
 
Sterilize the glucose and urea solutions by filtration. Prepare the basal 
medium without glucose and urea, adjust to pH 6.8-6.9 and sterilize by autoclaving  
in a flask at 121°C for 30min. Cool to about 50°C, add the glucose & urea, and tube 
the medium as slopes. 
 
5. Simmon’s Citrate Medium 
 
Koser’s medium       1 ltr 
Agar         20g  
Bromothymol blue(0.2%)                  40ml 
Dispense, auto clave’ at 121°C for 15 min and allow to set as slopes 
 
6. Triple Sugar Iron medium 
Beef  Extract                                        3g  
Yeast extract                     3g  
Peptone                                    20g  
Glucose                1g  
Lactose                                l0g  
Sucrose                                     l0g  
Ferric citrate                                       0.3g  
Sodium chloride                                 5g 
Sodum thiosulphate    0.3g  
Agar                                       12g  
Phenol red 0.2% solution                l2ml  
Distilled water     1ltr 
 
Heat to dissolve the solids, add the indicator solution, mix and tube. Sterilize 
at  121°C  for  15  min and cool to form slopes with deep butts. 
 
 
7. Glucose phosphate broth 
 
Peptone                                           5g  
Dipotassium hydrogen phosphate                  5g  
Water                                                             1ltr 
Glucose10%solution                             50ml 
 
Dissolve the peptone and phosphate and adjust the Ph to 7.6. Filter dispense 
in  5ml amounts and sterilize at  121°c for 15min. Sterilize the glucose solution by 
filtration and add 0.25ml to each tube. 
 
Methyl Red Reagent 
Methyl Red                                  10mg  
Ethyl alcohol           30ml  
Distilled water                             20ml 
 
Voges Proskauer Reagent 
Reagent A: Alpha naphthol   5g  
Ethyl alcohol                                     100ml  
Reagent B: Potassium hydroxide       40g  
Distilled water                                    100ml 
 
8. Peptone water fermentation test medium. 
 
To the basal medium of peptone water, add sterilised sugars of 1% 
 
Indicator  
Bromothymol blue with Durham’s tube. 
 
 
Basal medium peptone water 
Sugar solutions: 
Sugar                                                              1ml 
Dislilled water                                                l00ml 
pH=7.6. 
9. Mannitol motility medium 
Agar                                              5g  
Peptone                                     1g  
Potassium nitrate                       1g  
Mannitol                             2g  
Phenol red indicator 
Distilled water        l000ml  
pH=7.2 
 
10. Potassium nitrate broth 
Potassium nitrate (KN03)      0.2gm  
Peptone                      5.0gm  
Distilled water                             100ml 
The above ingredients were mixed and transferred into tubes in 5ml amount 
and auto claved. 
 
11. Phenyl alanine deaminase test 
Yeast Extract                  3g  
Dl-Phenylalamine    2 g  
Disodium hydrogen phosphate                 l g  
Sodium Chloride                       5 g 
Agar                                               12g  
Distilled water                  1 lr 
pH=7.4 
 
Distributed in tube sand sterilized by autoclaving at121°C for 15 minutes, 
allowed to solidify as long slopes. 
 
12. Sugar fermentation medium 
 
Peptone                                              15g  
Andrade’s indicator                       10ml  
Sugar to be tested                     20g  
Water                          1litre 
 
Andrade’s indicator is prepared from 0.5% aqueous acid fuchsin to which 
sufficient 1M sodium hydroxide has been added to turn the colour of the solution 
yellow. 
 
Dissolve the peptone and Andrade’s indicator in 1litre of water and add 20g of the 
sugar; sugars to be tested generally include glucose, sucrose, lactose and maltose. 
Distribute 3ml amounts in standard test tubes containing an inverted Durham tube. 
Sterilize by steaming at 100°C for 30min on 3 consecutive days. 
 
13. Sugar assimilation agar 
 
Basal medium I 
Yeast nitrogen base(Difco) 
Agar 
Water 
 
Steam to dissolve and dispense in  10ml amounts in  universal containers. 
Autoclave at 115° C for 15min. 
  
ANNEXURE   II 
PROFORMA 
Name       S. No. 
Father’s name     IP No 
Age       Date of sample collection 
Sex       Specimen 
Address      Test 
Family income 
Chief complaints 
Past history 
Personal history of smoking 
Occupational history 
History of Co-Morbid Illness 
Family history 
 
CLINICAL DIAGNOSIS 
 
PHYSICAL EXAMINATION 
 
 
  
ANNEXURE   III 
CONSENT FORM 
STUDY TITLE 
“A STUDY OF MICROBIOLOGICAL PROFILE IN OBSTRUCTIVE 
PULMONARY DISEASE IN A TERTIARY CARE HOSPITAL IN THANJAVUR” 
 
I ………………………………..hereby give consent to participate in the study conducted 
by Dr. M. Lidwin Mary, Post Graduate in Thanjavur Medical College, Thanjavur to use 
my personal clinical data and the result of investigations for the purpose of analysis and 
to study the nature of the diseases. I also give consent to give my sputum for further 
investigations. I also learn that there is no additional risk in this study. I also give my 
consent to the investigator to publish the data in any form or journal. 
 
Signature/Thumb impression    Place: 
Of the patient/relative     Date 
Name of patient & Address 
Signature of investigator 
Signature of Guide      
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